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Abstract: CD95 ligand (CD95L) is expressed by immune cells and triggers apoptotic death. 
Metalloprotease-cleaved CD95L (cl-CD95L) is released into the bloodstream but does 
not trigger apoptotic signaling. Hence, the pathophysiological role of cl-CD95L 
remains unclear. We observed that skin-derived endothelial cells from systemic lupus 
erythematosus (SLE) patients expressed CD95L, and that after cleavage, cl-CD95L 
promoted T helper 17 (Th17) lymphocyte transmigration across the endothelial barrier 
at the expense of T regulatory cells. T cell migration relied on a direct interaction 
between the CD95 domain called calcium-inducing domain (CID) and the Src 
homology 3 domain of phospholipase Cγ1. Th17 cells stimulated with cl-CD95L  
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 produced sphingosine-1-phosphate (S1P), which promoted endothelial transmigration by 
activating the S1P receptor 3. We generated a cell-penetrating CID peptide that prevented 
Th17 cell transmigration and alleviated clinical symptoms in lupus mice. Therefore, 
neutralizing the CD95 non-apoptotic signaling pathway may be attractive therapeutic 
approach for SLE treatment. 
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Cover Letter 
Oncogenesis, Stress & Signaling Laboratory 
Université de Rennes-1 - INSERM ERL440 
Centre de Lutte Contre le Cancer Eugène Marquis 
Rennes, 17 June, 2016 
To Editors of Immunity, 
We are pleased to submit a re-revised version of our manuscript IMMUNITY-D-15-
00834R3, for publication in Immunity. The title changed according to Miss Kavitha Scranton 
recommendations; New Title is "CD95 recruits PLCγ1 to trigger a calcium response 
promoting Th17 accumulation in inflamed organs of lupus mice". 
All reviewer#2 remarks have been addressed in the main text of the manuscript. 
Overall, this work highlighted that cl-CD95L, found in high levels in SLE patients, 
leads to Th17 accumulation in inflamed organs in this autoimmune disease. Moreover, we 
revealed that CD95-mediated non-apoptotic signaling can be specifically blocked to prevent 
its pro-inflammatory effect and that treatment designed to halt cl-CD95L actions in vivo 
alleviates both the immune and pathological hallmarks in lupus-prone mice. Ultimately, our 
findings support further investigations into targeting of the cl-CD95L pathway in autoimmune 
inflammation and specifically SLE and provide the proof-of-concept for novel therapeutic 
avenues for this devastating disease. 
We are confident that by addressing all reviewer concerns, you now consider this study 
satisfactory for publication in Immunity. 
We look forward to hearing from you at your earliest convenience. 
 
Dr. Patrick Legembre 
Oncogenesis, Stress & Signaling Laboratory 1 
ER440 - Université Rennes 1 - Centre de Lutte Contre le Cancer Eugène Marquis 
Rue de la Bataille Flandres Dunkerque - CS 44229-35042 RENNES 
CEDEX Phone: (+33) 2 99 25 31 90 - Fax: (+33) 2 99 25 31 64 
 Response to Reviewers 
Reviewer #2: a. The recruitment of PLCg1 to Fas 
1. The data about the co-immunoprecipitation in extract of CEM cells, which are presented 
in supplementary figure 5B and in reviewer-figure 1 are consistent and seem reliable. 
Ok .  
2. Figure 4A is not reliable. The density within the bands varies (e.g. that of 1 min). At face 
value this figure implies that the extent of binding of PLCg1 to the receptor decreases (e.g. at 
10 minutes) much below the background control (B), which is an absurd. This figure must not 
be presented. 
Figure 4A has been replaced by reviewer-figure 1 as suggested by the reviewer. 
3. The proximity ligation assay (PLA): These data are exciting. However, two things need 
clarification. (a) Why is the kinetics of association indicated by this assay (prolonged 
association) so different from the kinetics revealed by co-immunoprecipitation (very transient 
association). (b) The PLA seems to imply occurrence of one or two foci of association of 
PLCg1 with Fas per cell. This is strange. Fas normally does not form such loci, not even after 
ligand binding. To confirm validity of the test the authors should present the patterns of 
immunostaining with anti-Fas (and if possible also with anti PLCg1). To allow telling where 
the cell membrane is, the authors should also present superposition of the PLA picture with 
light microscope image. 
You are right. Usually, CD95 stimulation leads to the formation of CD95 aggregation 
and formation of CD95 “cap” at the membrane of T cells (Algeciras-Schimnich et al., 
2002; Chaigne-Delalande et al., 2009). Our data confirmed that CD95 is at the 
membrane (contrast analyses, data not shown). 
It is noteworthy that PLA is a different method from co-localization experiments 
performed with two fluorochrome-conjugated antibodies. Indeed, PLA requires a step 
of PCR reaction to reveal the protein co-localization and this process may account for 
the dot pattern observed in our experiments instead of a larger aggregation of CD95 
(cap pattern) as observed upon CD95 stimulation. 
b. The involvement of PSGL-1 upregulation and of sphingosine-1-phosphate (S1P) signaling 
pathway in the CD95L effect  
The main contribution of this study is the definition of the CID and of its function. Whether 
upregulation of PSGL-1 and the S1P pathway contribute to this function is of lesser 
importance and to my mind could have been ignored in this paper without greatly harming its 
significance. However, if the authors do choose to refer to these issues they must opt for the 
right terms in qualifying the solidity of their evidence. 
 
We tempered our claim as suggested by reviewer (in red in our main text). 
1. Involvement of PSGL-1 upregulation in the increased transmigration. The fact 
that E-selectin-neutralizing antibody blocked the transmigration teaches that E - 
Oncogenesis, Stress & Signaling Laboratory 1 
ER440 - Université Rennes 1 - Centre de Lutte Contre le Cancer Eugène Marquis 
Rue de la Bataille Flandres Dunkerque - CS 44229-35042 RENNES 
CEDEX Phone: (+33) 2 99 25 31 90 - Fax: (+33) 2 99 25 31 64 
 selectin/PSGL-1 interaction is required for the transmigration (as do may other cellular 
functions - that of the cytoskeleton for example). It does not teach that this interaction is the 
target of CD95L ligand. The facts that PSGL-1 is already expressed in the absence of CD95L 
and that CD95L induces rather limited increase of this expression in fact speak against this 
possibility. Stating that their findings “established that cl-CD95L promotes a selective Th17 
cell transmigration by increasing PSGL-1/E-selectin interactions” is wrong. 
Claim has been tempered as suggested by reviewer. 
2. In support of the idea that the S1P pathway mediates the effect of CD95L on transmigration 
the authors show that (a) CD95L upregulates proteins that take part in the pathway. (b) CD95L 
enhances generation of S1P, (b) chemical inhibitors blocking the pathway abolish the increase 
in transmigration. What they don’t provide is any information of the mechanism by which the 
S1P pathway might mediate this effect. Given the limitation of specificity of any chemical 
inhibitor and the possibility that activation of this pathway by CD95L serves other functions I 
would recommend that the authors will temper their statement about their conclusions from the 
data. The statement “We demonstrated that this process occurs via activation of the 
sphingosine-1-phosphate (S1P) signaling pathway” is not justified. In addition, if the authors 
choose not to present in this paper the evidence that S1P generation is upregulated by CD95L 
they must at least state in it that they have such evidence and that it will be presented 
elsewhere. 
S1P experiments have been kept in the last version of this study. We have tempered our 
claim. 
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ABSTRACT 
CD95 ligand (CD95L) is expressed by immune cells and triggers apoptotic death. 
Metalloprotease-cleaved CD95L (cl-CD95L) is released into the bloodstream but does not 
trigger apoptotic signaling. Hence, the pathophysiological role of cl-CD95L remains unclear. 
We observed that skin-derived endothelial cells from systemic lupus erythematosus (SLE) 
patients expressed CD95L, and that after cleavage, cl-CD95L promoted T helper 17 (Th17) 
lymphocyte transmigration across the endothelial barrier at the expense of T regulatory cells. 
T cell migration relied on a direct interaction between the CD95 domain called calcium-
inducing domain (CID) and the Src homology 3 domain of phospholipase Cγ1. Th17 cells 
stimulated with cl-CD95L produced sphingosine-1-phosphate (S1P), which promoted 
endothelial transmigration by activating the S1P receptor 3. We generated a cell-penetrating 
CID peptide that prevented Th17 cell transmigration and alleviated clinical symptoms in lupus 
mice. Therefore, neutralizing the CD95 non-apoptotic signaling pathway may be attractive 
therapeutic approach for SLE treatment. 
Key words: Calcium, CD95, inflammation, lupus, sphingosine-1 phosphate, Th17 cell 
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INTRODUCTION 
CD95 ligand (CD95L, also known as FasL) is a transmembrane glycoprotein that acts locally 
through cell-to-cell contact (Suda et al., 1993). The extracellular domain of CD95L comprises a 
juxtamembrane stalk region (Orlinick et al., 1997) that is cleavable by metalloproteases 
(Fouque et al., 2014), and this cleavage releases CD95L into the bloodstream. CD95 (also 
known as Fas, APO-1, and TNFRSF6) belongs to the tumor necrosis factor receptor (TNF-R) 
family and is ubiquitously expressed in the body (Peter et al., 2015). When membrane-bound 
CD95L binds to CD95, the intracellular region of CD95 (designated the death domain - DD) 
orchestrates the formation of a death-inducing signaling complex (DISC) by recruitment of the 
adaptor molecule, Fas-associated protein with death domain (FADD), which in turn induces 
caspase-8 aggregation and subsequent apoptosis (Kischkel et al., 1995). Contrarily, we and 
others have shown that metalloprotease-cleaved CD95L (cl-CD95L) promotes formation of an 
atypical molecular complex designated motility-inducing signaling complex (MISC) that 
stimulates non-apoptotic signaling pathways and increases intracellular calcium (Ca2+) content 
(Kleber et al., 2008; Malleter et al., 2013; Tauzin et al., 2011). 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder of largely unknown 
etiology whose pathogenesis can affect almost all organs and tissues. Human studies and 
murine models indicate a role for IL-17-producing T helper 17 (Th17) cells in SLE 
progression (see (Shin et al., 2011) for a review). Lupus-prone mice are partially protected 
from immunopathology by a reduction in renal Th17 cell accumulation (Steinmetz et al., 
2009). Therefore, abnormal Th17 cell trafficking to inflamed organs may promote SLE 
pathogenesis, and modulation of Th17 cell migration is an attractive therapeutic option for 
reducing disease-related inflammation. However, the precise mechanism of Th17 cell 
accumulation in damaged SLE organs remains unclear. 
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A close relationship exists between SLE pathogenesis and deregulation of CD95 signaling 
already. Patients suffering from autoimmune lymphoproliferative syndrome (ALPS) type Ia 
harbor mutations in CD95 responsible for lymphoproliferation and SLE-like autoimmunity 
(Drappa et al., 1996; Fisher et al., 1995; Rieux-Laucat et al., 1995). These ALPS type Ia 
patients show heterozygous mutations (Straus et al., 2001) leading to the inhibition of the 
CD95-mediated apoptotic signal without affecting activation of non-apoptotic signaling 
pathways (Legembre et al., 2004). Accordingly, we hypothesize that aggravation of lupus 
symptoms is not only caused by a defective apoptotic process (Kuhtreiber et al., 2003) but 
also by induction of CD95-mediated non-apoptotic signaling pathways. 
Herein, we demonstrated that high concentrations of cl-CD95L in SLE patients promoted 
Th17 cell migration across the endothelial barrier at the expense of regulatory T (Treg) cells in 
a Ca2+-dependent manner. This CD95-mediated Ca2+ signaling occurred independently of the 
CD95-DD and exploiting this result, we designed a therapeutic molecule that selectively 
neutralized the CD95-mediated non-apoptotic signaling pathways. Moreover in a murine 
model of SLE, this treatment halted the pro-inflammatory actions of cl-CD95L, alleviating 
both immune and pathological hallmarks of SLE. 
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RESULTS 
CD95L in SLE serum promotes endothelial transmigration of activated Th17 cells 
Soluble CD95L concentrations in serum obtained from SLE patients were higher than those 
from age-matched healthy donors (Fig. 1A). SLE serum was fractionated by size-exclusion 
chromatography (Fig. 1B). By ELISA, CD95L was mainly detected in fractions 76–78; the 
proteins in these fractions showed molecular masses ranging from 75 to 80 kDa under native 
conditions. Next, CD95L was immunoprecipitated from these fractions, revealing under 
denaturing conditions, a polypeptide band of 26 kDa (Fig. 1B). These results do not rule out 
the possibility that soluble CD95L is associated with another partner but strongly suggest that 
serum CD95L in SLE patients corresponds to a homotrimeric ligand. 
We next hypothesized that if serum CD95L contributes to inflammatory processes in SLE 
patients by promoting extravasation of Th17 cells in inflamed tissues, then CD95L-expressing 
cells should be detected in these tissues and surrounded by IL-17-expressing cells. Therefore, 
we performed an immunohistochemical analysis of skin biopsies obtained from SLE patients 
to examine the distribution of CD95L- and IL-17-expressing cells. Skin biopsies from SLE 
patients, but not from healthy controls, showed positive staining for CD95L and IL-17 (Figs. 
1C and S1). CD95L expression was mainly restricted to blood vessel endothelial cells, and 
these cells were surrounded by infiltrating immune cells (Figs. 1C and S1). Serial slices of 
skin biopsies from SLE patient revealed that IL17 was co-expressed by CD4+ T cells (Fig.1D), 
indicating that CD95L-expressing blood vessels were surrounded by infiltrating Th17 cells. 
Moreover, a densitometric analysis of stained tissues from lupus patients (n = 10) revealed a 
correlation between CD95L concentrations and the number of tissue-infiltrating, IL-17-
expressing immune cells (Fig. 1E). This suggested that CD95L may behave as a 
chemoattractant for Th17 cells. 
To examine whether after cleavage by metalloproteases, soluble CD95L had a  
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chemoattractive effect on all T cells or was selective for distinct Th cell subsets, we next 
evaluated transmigration of undifferentiated (Th0) and differentiated (Th1 and Th17) CD4+ T-
cells with or without serum from SLE patients. Compared with healthy serum, SLE serum 
triggered a moderate increase in Th1 cell transmigration and a marked increase in Th17 cell 
transmigration (Fig. 1F). Pre-incubation of SLE serum with a decoy CD95 receptor (CD95-
Fc) dose-dependently inhibited Th17 cell migration, indicating that transmigration of these 
cells relied on CD95 signaling (Fig. 1G). 
We produced a homotrimeric, metalloprotease-cleaved version of human CD95L (cl-
CD95L)(Tauzin et al., 2011). Similarly to CD95L in SLE serum, cl-CD95L more efficiently 
promoted the transmigration of Th1 and Th17 lymphocytes relative to undifferentiated Th0 
and differentiated Th2 cells (Fig. 1H). Because an imbalance between the Th17/Treg cell ratio 
in inflamed organs has been previously reported in the pathogenesis of SLE and other 
autoimmune disorders (Yang et al., 2009), we also examined the effect of cl-CD95L on Treg 
cell transmigration. Cl-CD95L increased the endothelial transmigration of in vitro-
differentiated Th17 cells, but not that of Treg cells (Fig. 1I). These results support that high 
concentrations of serum CD95L in SLE patients can cause pro-inflammatory Th17 cell 
accumulation and destabilize Th17/Treg cell balance in diseased organs. 
To determine the mechanism responsible for this preferential transmigration of Th17 cells, we 
examined the expression of adhesion molecules known to promote endothelial transmigration. 
Cl-CD95L had no effect on the expression concentrations of adhesion molecules expressed by 
human umbilical vein endothelial cells (HUVECs) (Fig. S1B). On the other hand, while 
stimulation of Th17 cells with cl-CD95L had no effect on the amount of lymphocyte function-
associated antigen-1 (LFA-1, the ICAM-1 binding partner), it led to upregulation of P-selectin 
glycoprotein-1 (PSGL-1, an E-/P-selectin ligand) (Fig. S1C). The concentration of PSGL-1 was 
also up-regulated in Th1 cells but to a lesser extent as compared to Th17 cells, and tended 
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to be downregulated in Treg cells (Fig. S1C). As HUVECs used in our transmigration assay 
expressed E-selectin but not P-selectin (Fig. S1B), we next examined whether blocking 
these E-selectin-PSGL-1 interactions could abrogate the CD95-mediated Th17 
transmigration. An E-selectin-neutralizing monoclonal antibody (mAb) inhibited Th17 cell 
transmigration while it did not affect the weak endothelial transmigration observed in Treg 
cells exposed to cl-CD95L (Fig. S1D). This antibody was more effective in preventing the 
CD95-mediated endothelial transmigration of Th17 cells when compared to Th1 cells (Fig. 
S1D). To understand why Th1 cells responded less efficiently to cl-CD95L than Th17 cells, 
we compared the quantity of CD95 in different Th subsets from 20 blood donors. While the 
amount of CD95 was not lower in Treg cells compared to Th17 cells (Fig.S1E), Th1 cells 
exhibited a reduced concentration of CD95 as compared to Th17 cells (Fig.S1E). This 
finding may then explain why Th1 cells migrated with a lower intensity in the presence of 
cl-CD95L when compared to Th17 cells. 
To address how cl-CD95L selectively promoted the endothelial transmigration of Th17 cells to 
the detriment of Treg cells, we investigated how cl-CD95L stimulation affected the gene 
expression profile of Th17 and Treg cells. Human Th17 cells (CD4+CXCR3-CCR6+CD45RA-) 
and Treg cells (CD4+CD127lowCD25+) were sorted from the blood of two different donors (Fig. 
S1F) and stimulated in the presence or absence of cl-CD95L. Transcriptomic signatures of Treg 
and Th17 cells stimulated with cl-CD95L were analyzed (Fig. 2A-B and Tables S1 and S2). 
Gene ontology analysis revealed that the sphingosine 1 phosphate (S1P) signaling pathway was 
modulated in Th17 cells stimulated with cl-CD95L (Fig. 2C) while Treg cells exposed to cl-
CD95L showed over-expression of genes responsible for the implementation of cell death (Fig. 
2C). The S1P signaling pathway (Fig. S1G) can promote endothelial transmigration of activated 
T and B lymphocytes leading to extra- or intravasation. Using Th17 and Treg cells sorted as 
aforementioned, we confirmed that cl-CD95L promoted 
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endothelial transmigration of Th17 cells but not Tregs (Fig.2D). Pre-incubation of Th17 cells 
with FTY720, a chemical that induces internalization of four S1P receptors (S1P-1, -3, -4 and 
-5) (Brinkmann et al., 2002) indicated that cl-CD95L selectively promoted endothelial 
transmigration of Th17 cells by stimulating the S1P signaling pathway (Fig. 2D). To evaluate 
the role of S1PR3 in the CD95-mediated Th17 transmigration, we next tested the effect of 
additional antagonist molecules, namely TY-52156 (Murakami et al., 2010), CAY-1044, 
VPC-23019, and W-146 (Li et al., 2015) (Fig. 2D) on Th17 cell migration. While the 
selective S1PR3 inhibitors, TY-52156 and CAY-1044, and the S1PR1 and S1PR3 inhibitor 
VPC-23019 efficiently inhibited the passage of Th17 cells across endothelial cells (Fig. 2D), 
the S1PR1 antagonist W146 did not prevent CD95-mediated Th17 transmigration (Fig. 2D). 
Overall, these findings established that cl-CD95L promotes a selective Th17 cell 
transmigration that partially relies on the increased PSGL-1-E-selectin interactions, the 
production of S1P and the implemention of the S1PR3-driven signaling pathway. 
Cl-CD95L recruits Th17 cells in vivo 
To demonstrate in vivo that cl-CD95L is a chemoattractant for Th17 cells, C57BL/6 mice were 
injected intraperitoneally with cl-CD95L, and infiltrating cells in the peritoneal cavity, the 
spleen and mesenteric lymph nodes (MLN) were examined 12, 24 and 48h later. The number 
of activated CD4+ T-cells recruited to these organs was evaluated in cl-CD95L-injected mice 
by using loss of CD62L as an indication of T-cell activation. While the total number of Th1 
and Treg cells did not change in the peritoneal cavity, spleen and MLNs of mice injected with 
cl-CD95L as compared to control medium-administrated mice (Fig. 3A), there was an 
accumulation of Th17 cells in the peritoneal cavity of cl-CD95L-injected mice and to a lesser 
extent in peripheral secondary lymphatic organs such as spleen and MLN (Fig. 3A,B). Real-
time quantitative polymerase chain reaction (qPCR) analysis of key Th17 lineage 
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markers (IL-17, IL-23R, and C-C chemokine receptor type 6 (CCR6)) of activated CD4+ T-
cells confirmed that cl-CD95L recruited Th17 cells to these tissues (Fig. S2A-C). No increase 
was observed in the number of cells expressing IFN-γ (indicative of Th1 cells) or FoxP3 
(indicative of Treg cells) (Fig. S2D & E), confirming that injection of cl-CD95L in the 
peritoneal cavity of immune-competent mice creates a gradient of cl-CD95L promoting the 
endothelial transmigration of Th17 cells. 
CD95 triggers a DD-independent Ca2+ response 
We previously showed that engagement of CD95 evoked a Ca2+ response in activated T 
lymphocytes, resulting in transient inhibition of cellular apoptosis (Khadra et al., 2011) and cell 
migration (Malleter et al., 2013; Tauzin et al., 2011). Due to the instrumental role of the CD95-
mediated apoptotic signal in anti-infectious and anti-tumor responses, we assumed that the 
inhibition of the CD95 non-apoptotic responses while conserving the apoptotic signal could be 
an attractive therapeutic option to prevent Th17 recruitment in inflamed organs without altering 
immune surveillance. We then wondered whether it was possible to selectively inhibit the 
CD95-mediated Ca2+ response and whether this blockade could inhibit cell migration without 
blocking the apoptotic signal. Human T-cells exposed to cl-CD95L rapidly formed a transient 
molecular complex containing phospholipase Cγ1 (PLCγ1) (Fig. 4A). Using proximity ligation 
assay (PLA), we confirmed that this interaction was selective of CD95 and occurred in a 
transient and rapid manner (Fig. S3A). CD95-PLCγ1 interaction was not detected in CEM-IRC 
cells, which express a faint amount of endogenous CD95 (Beneteau et al., 2008) and the peak 
of interaction in parent CEM T cells was reached 5 minutes after addition of cl-CD95L (Fig. 
S3A). Moreover, the lack of PLCγ1 in T-cells resulted in a loss of CD95-mediated Ca2+ 
response (Fig. S3B). PLA experiments also revealed that CD95 rapidly recruited PLCγ1 in 
Th17 cells exposed to cl-CD95L (Fig.4B). We next 
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investigated whether the predominant DISC components, FADD and caspase-8, might 
contribute to CD95-mediated Ca2+ signaling. FADD and caspase-8-deficient Jurkat T cells 
(Juo et al., 1998; Juo et al., 1999) exposed to the cytotoxic CD95L showed no apoptotic 
signaling (Fig. S3C), but the CD95-mediated Ca2+ signaling pathway remained unaffected in 
these cells (Fig. S3D) suggesting that PLCγ1 activation occurs independently of CD95-DISC 
and cell death signaling. To further investigate whether the death domain (DD) of CD95 was 
involved in the Ca2+ response, we generated CD95 constructs devoid of the entire intracellular 
domain of CD95 (CD951–175), the DD (CD951–210), or the last 15 aa involved in FAP-1 protein 
tyrosine phosphatase recruitment (CD951–303) (Sato et al., 1995) (Fig. 4C). These constructs 
were expressed in the CEM-IRC T-cell line, which was selected for its low CD95 expression 
(Fig. S3E). 
A CD95-deficient CEM cell designated CEM-IRC (described in (Beneteau et al., 2007)) cells 
showed minimal cell death in response to a multimeric (dodecamer) and cytotoxic CD95L 
(IgCD95L, Fig. S3F); however, expression of CD951–303 or wild-type CD95 restored cell 
death levels to those observed for parental CEM cells (Fig. S3F). Contrarily, introduction of 
CD951–175 or CD951–210 failed to induce apoptosis and, as previously observed, these 
constructs behaved as dominant-negative receptors (Fig. S3F)(Siegel et al., 2000). 
Furthermore, reconstituting CEM-IRC cells with wild type CD95 or CD951–303 restored 
CD95-mediated Ca2+ signaling (Fig. 4D). 
Whereas the loss of the DD from the CD951–210 construct prevented apoptotic signaling, 
CD95-DD deletion did not affect induction of Ca2+ signaling (Fig. 4D). Given that a CD95 
construct devoid of the entire intracellular region (CD951–175) failed to evoke a Ca2+ response, 
we concluded that Ca2+ signaling was triggered by CD95 aa 175–210. 
We next examined whether CD951–210 was capable of recruiting PLCγ1. To this end, we 
transiently co-transfected HEK cells with green fluorescent protein (GFP)-fused CD95 
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constructs and wild-type PLCγ1. Although the transfected cells expressed similar quantity of 
CD95-GFP chimeric constructs at the cell surface (Fig. S3G), PLCγ1 was absent only from the 
CD951–175 immunoprecipitate (Fig. 4E). To demonstrate that amino acid residues 175-210 of 
CD95 contributes to PLCγ1 recruitment, we generated a construct comprising CD95175–210 
(termed the calcium-inducing domain (CID)) fused to the fluorescent protein mCherry. Unlike 
mCherry alone, CD95175–210-mCherry interacted with PLCγ1 and inhibited its recruitment to 
CD95 (Fig. S3H), suggesting that interference with this juxtamembrane domain may prevent 
CD95-mediated Ca2+ signaling. 
To confirm this hypothesis, we synthesized a cell-penetrating peptide, TAT-CID, by linking 
CID to the nine-aa human immunodeficiency virus (HIV)-TAT sequence (Fig. S4A), which 
serves as a carrier for protein translocation across the plasma membrane (Vives et al., 1997). 
Pre-incubation of activated peripheral blood lymphocytes (PBLs) with TAT-CID impaired the 
recruitment of PLCγ1 (Fig. 4F) and abolished the induction of CD95-mediated Ca2+ signaling 
(Fig. 4G). Similarly, pre-incubation of CEM cells with TAT-CID inhibited PLCγ1 binding to 
CD95 (Fig. S4B) and abrogated the CD95-induced Ca2+ response in Jurkat and CEM T-cell 
lines (Fig. S4C). TAT-CID also reduced Akt phosphorylation at serine 473 (a hallmark of 
PI3K signaling activation) in cl-CD95L-exposed PBLs (Fig. S4D) confirming a role of 
calcium in the modulation of the PI3K signaling pathway (Malleter et al., 2013). Nevertheless, 
although TAT-CID impeded CD95-mediated Ca2+ and PI3K signaling, the peptide did not 
affect the apoptotic signaling pathway (Fig. S4E). Hence, we mapped a domain in CD95 
receptor, namely CID, which recruits PLCγ1 and elicits Ca2+ responses. 
CID interacts with the SH3 domain of FLCγ1 
To address whether CD95 directly interacts with PLCγ1, we performed a Renilla luciferase-
based protein fragment complementation assay (RLuc-PCA) (Stefan et al., 2007). The Renilla 
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luciferase enzyme was divided into two fragments. Each fragment (F1 and F2) was fused to 
various CD95 and PLCγ1 domains and co-transfected in HEK cells (Figs. S5A-D). Only 
PLCγ1-SH3 interacted with the whole CD95 intracellular region and CD95-CID, but failed to 
reconstitute enzyme activity when combined with CD95-DD (Fig. 5A,B). To strengthen this 
result, we evaluated whether the cell-penetrating TAT-CID peptide could inhibit the 
interaction of PLCγ1-SH3 with CD95-CID. While TAT-control peptide did not alter 
luciferase activity in cells co-expressing PLCγ1-SH3-F1 and CD95-CID-F2, TAT-CID 
efficiently blocked this activity in a dose-dependent manner (Fig. 5C), supporting the 
hypothesis that CD95 directly associates with PLCγ1 through the CD95-CID domain. 
Intriguingly, SH3 domains primary bind to peptides containing a consensus PxxP sequence 
that is not present in CID; however, many examples of unconventional SH3-binding peptides 
have previously been described (Saksela and Permi, 2012). 
To understand how CD95 CID might interact with PLCγ1-SH3, we undertook two 
computational peptide screenings. First, we performed homology modeling by using the 
crystal structure of PLCγ1-SH3 in association with the SLP-76 heptapeptide complex 
(PDB:1YWO) (Deng et al., 2005). This structure served as a template, and the SLP-76 peptide 
was replaced by each heptapeptide combination present in CD95-CID. Second, a protein-
peptide docking approach was carried out by using each aforementioned CID heptapeptide 
alternatively docked within the PLCγ1-SH3 domain. Both methods predicted that aa 182–188 
(TCRKHRK) would have the highest affinity for PLCγ1-SH3, and the calculated binding 
energy of the complex consisting of PLCγ1-SH3 and TCRKHRK was similar to that of the 
PLCγ1-SH3 interaction with SLP-76 (Fig. 5D and Table S3). To prove that the TCRKHRK 
amino acid sequence corresponded to the minimal domain interacting with PLCγ1, we first 
used RLuc-PCA and performed an alanine-scanning experiment. This confirmed that amino 
acid residues R184, K185, K188 were instrumental in the interaction of 
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CD95 with PLCγ1 (Fig. S5E). In agreement with this cell-based assay, our computer model 
identified an interaction between R184 guanidine and SH3-PLCγ1 through a hydrogen bond 
network involving amino acids Y845 and Q805 side-chains and K803 backbone. K185 amine 
function forms hydrogen bonds, in an intramolecular manner, with H186 backbone and with 
G826 backbone of SH3-PLCγ1. A salt bridge occurred between K188 and E825. Furthermore, 
the positioning of K188 in the SH3 cavity required the displacement of a water molecule 
(H2O105 observed in the crystal structure), an entropically favourable process. For this solvent 
exposed interface, the methylene chain of these basic residues form extensive van der Waals 
contacts with the SH3 hydrophobic shallow pockets. Overall, these observations indicated that 
even if the CID sequence is not related to a typical class II ligand of SH3, it complies with its 
properties in terms of van der Waals interactions (Deng et al., 2005). Of note, RLuc-PCA also 
revealed that glutamic acid 189, localized outside the minimal TAT-CID domain, participated 
in the binding of CD95 with PLCγ1 (Fig. S5E). This amino acid may play a role of “compass 
residue” evoked for typical proline-rich SH3 ligands (Musacchio, 2002). Indeed, the canonical 
PxxP motif-containing peptides could be docked in two opposite orientations regarding the 
relative positioning of a positively charged residue (+xxPxxP or xPxxPx+) interacting with a 
negatively charged cleft on the SH3 surface (Saksela and Permi, 2012). Similarly to this basic 
amino acid in the PXXP motif, E189 could contribute to the positioning of the minimal CD95-
CID peptide in the PLCγ1 SH3 domain. Secondly, we generated two constructs, a CD95 in 
which R184 and K185 were replaced by alanine (double mutant or DM) and a CD95 in which 
R184, K185 and K188 (triple mutant or TM) were replaced by alanine. These two constructs 
and a wild type CD95 were transfected into HEK cells and the CD95-mediated Ca2+ response 
was evaluated in these cells. HEK cells express endogenous wild type CD95 and thereby 
expression of our constructs was expected to create heterotrimeric complexes consisting of 
wild type and mutated CD95, which could 
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inhibit PLCγ1 recruitment in a dominant negative fashion. Both double and triple mutants 
abrogated the CD95-mediated Ca2+ signaling pathway (Fig. S5F). For each amino acid, we 
also generated single mutation. Strikingly, these mutants when expressed in HEK cells, did 
not alter the CD95-mediated calcium signaling pathway (data not shown) suggesting that 
unlike double and triple mutants, PLCγ1 recruitment could accommodate to a single mutation 
inside the minimal CID. As CID corresponds to a disorganized domain, we surmised that to 
increase PLCγ1 binding affinity, a larger zone of contact is mandatory and that elimination of 
only one amino acid may not be sufficient to impair this recruitment in a heterotrimeric 
complex containing wild type CD95. Overall, these findings indicated that the CD95-CID 
amino-terminal region corresponded to an unconventional SH3-binding peptide. 
To confirm our in silico result, we synthesized two cell-penetrating peptides consisting of the 
amino- and carboxyl-terminal regions of CD95 CID (CID-N, corresponding to aa 175–192, 
and CID-C, corresponding to aa 193–210) (Fig. S5G). We then evaluated their effects on the 
CD95-mediated Ca2+ response (Fig. 5E), and showed that only CID-N abrogated CD95-
mediated Ca2+ signaling in Jurkat cells and activated PBLs (Fig. 5E). Taken together, these 
findings demonstrated that the juxtamembrane region of CD95 directly interacts with PLCγ1-
SH3 to evoke Ca2+ signaling. 
Lastly, we examined whether the inhibitory actions of TAT-CID were selective for CD95-
mediated Ca2+ signaling. Although T-cell receptor (TCR) stimulation led to a PLCγ1-
dependent Ca2+ response in Jurkat cells (Fig. S5H), pre-treatment with the TAT-CID peptide 
had no such effect (Fig. S5I). Similarly, TAT-CID did not influence the PLCβ-driven Ca2+ 
response stimulated by carbachol, a cholinergic agonist that activates G-protein-coupled 
receptors to release calcium (Fig. S5J). Therefore, TAT-CID selectively inhibits CD95-
mediated Ca2+ signaling. 
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Inhibition of CD95-mediated Ca2+ signaling prevents Th17 cell transmigration in vivo 
To assess the potential of TAT-CID as a therapeutic agent for SLE patients, we first examined 
its effect on Th17 cell transmigration. Figure 6A shows that TAT-human CID (TAT-hCID) 
dose-dependently inhibited CD95-mediated endothelial transmigration of human Th17 cells. 
Alignment of the human and mouse CD95 protein sequences highlighted differences in the 
CID region (21.2% sequence identity) (Fig. S6A). We reconstituted human CEM-IRC cells 
with mouse CD95 (Fig. S6B). CD95-mediated apoptotic signaling was restored in the mouse 
CD95-expressing cells, but not in the parental CEM-IRC cells (Fig. S6B). TAT-mouse CID 
(TAT-mCID), but not TAT-hCID, inhibited the mouse CD95-mediated Ca2+ response (Fig. 
S6C,D). Similarly, TAT-mCID also inhibited the CD95-mediated Ca2+ response in mouse T 
lymphocytes (Fig. S6E), indicating that despite differences in the human and mouse CD95-CID 
sequences, both domains trigger Ca2+ signaling. 
We next injected C57Bl/6 mice with TAT-control or TAT-mCID prior to the intraperitoneal 
injection of cl-CD95L, and then determined the number of T-cells infiltrating the peritoneal 
cavity 24 h later. TAT-mCID treatment reduced the CD95-mediated accumulation of 
peritoneal exudate cells (PECs) (Fig. 6B) and CD4+ lymphocytes (Fig. 6C). In agreement 
with the data shown in Figure 3, cl-CD95L injection increased IL-17 levels in the peritoneal 
cavity, but the increase was overturned by TAT-mCID pre-treatment (Fig. 6D). These 
findings indicated that TAT-CID inhibits cl-CD95L-mediated recruitment of IL-17-secreting 
CD4+ T-cells in vivo. 
TAT-CID alleviates clinical outcomes in lupus-prone MRL/lpr mice 
Patients suffering from ALPS type Ia exhibit CD95 mutations that cause SLE-like 
autoimmunity (Drappa et al., 1996; Fisher et al., 1995; Rieux-Laucat et al., 1995). 
Heterozygous Lpr+/− mice express reduced levels of CD95 due to insertion of a 
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retrotransposon into intron 2 of the CD95 gene and develop lupus (Adachi et al., 1993). T cells 
from both ALPS type Ia patients and MRL/lpr+/− mice show loss of sensitivity to CD95-
mediated apoptosis, but retain normal activation of non-apoptotic signaling pathways 
(Legembre et al., 2004). We asked whether the implementation of CD95-mediated non-
apoptotic signaling pathways in lupus mice contributed to symptom severity. Because TAT-
CID inhibited CD95-mediated Ca2+ response without affecting apoptotic signaling (Fig. S4C– 
E), this peptide allowed us to address this question. 
TAT-mCID and TAT-control peptides were administered to lpr+/− heterozygote mice. After 
completion of the trial, animals were sacrificed, revealing an alleviation of splenomegaly in 
TAT-CID-treated mice relative to controls (Fig. 6E), without any negative effect on whole-
body weight (Fig. S6F). Likewise, TAT-CID significantly reduced the weights of the 
inflamed kidneys and the mesenteric lymph nodes (Fig. S6G). Examination of the cellular 
composition of the spleen in lpr+/− mice revealed a significant decrease in total spleen cell 
number (Fig. 6F) and activated CD4+ T-cells (Fig. 6G), but not B-cells (Fig. S6H). 
Additionally, TAT-CID significantly decreased Th17 cell infiltration in the spleen of TAT-
CID- vs. TAT-control-treated mice, as indicated by reduced expression levels of Ccr6 and 
Il23r, and to a lesser extent Rorc, three key molecular markers of Th17 cells (Fig. 6H). Re-
stimulation of spleen-infiltrating CD4+ T-cells confirmed that the immune cells failed to 
produce IL-17A in TAT-CID-treated mice (Fig. 6I). 
Examination of the kidneys in lpr+/− mice demonstrated that TAT-CID vs. TAT-control 
decreased cell infiltration (Fig. 7A–C). The reduction in cellular infiltration in TAT-CID-
treated lpr+/− mice was translated into a reduction of glomerulus damage (Fig. 7D–F). The 
number of cells infiltrating the glomeruli was significantly lower in TAT-CID-treated mice as 
compared to TAT-control mice, resulting in significant swelling and loss of shape of the 
glomeruli in these latter mice (Fig.7D vs 7E). Moreover, improvement of the kidney 
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architecture in TAT-CID-treated mice (Fig. 7F) was associated with a decreased deposition of 
C3 activation fragments as compared to TAT-control mice (Fig.7G). Accordingly, organ 
function was restored in mice treated with repeated injections of TAT-CID as compared to 
TAT-control-treated mice with reduction of blood concentrations of creatinine and urea (Fig. 
7H). In parallel, serum concentrations of anti-dsDNA IgG1 were lower in TAT-CID mice than 
in TAT-control treated MRL/Lpr+/- mice (Fig.7I). When kidneys of TAT-CID and TAT-control 
treated Lpr+/- mice were analyzed, we found a lower number of CD4+IL17+ cells in the TAT-
CID group as compared to TAT-control treated mice (Fig.7J). While CD4+IFN-γ+ cell number 
tended to be lower in TAT-CID treated mice than in control mice, this effect was non-
significant (Fig.7J). Treatment efficiency supported our prediction that CD95-induced non-
apoptotic signaling pathways contribute to lupus severity and progression. 
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DISCUSSION 
An initial study showing that activated T cells transmigrated in the presence of cl-CD95L 
through the implementation of PI3K and Ca2+ signaling pathways (Tauzin et al., 2011), raised 
the question of whether all T-cells responded similarly to cl-CD95L and whether it was 
possible to selectively inhibit the CD95-mediated pro-inflammatory signaling pathway 
without affecting the apoptotic cues. While the death domain of CD95 is instrumental in the 
induction of the PI3K signaling pathway (Tauzin et al., 2011), we here provided evidence that 
the Ca2+ response stemmed from a different region within CD95 that we identified and 
designated calcium inducing domain (CID). 
CD95L+ blood vessels in skin of SLE patients were surrounded by infiltrating immune cells, 
suggesting that these structures could serve as “gateways” for inflammatory leukocytes and 
the ensuing recruitment of Th17 cells. By contrast, a recent study showed that CD95L 
expressed on endothelial cells functions to eliminate CD8+ T-cells and in doing so, prevents 
effective anti-tumor immunity (Motz et al., 2014). Examination of the CD8+ T cell infiltrate 
surrounding CD95L+ blood vessels in SLE patients revealed no inverse correlation between 
CD95L expression and the number of infiltrating CD8+ T-cells (Fig. S7A,B). Given that 
CD95L exerts its chemoattractant activity only after cleavage by metalloproteases (Tauzin et 
al., 2011), the observed discrepancy between the amount of immune infiltrate surrounding 
CD95+ blood vessels in cancer subjects and SLE patients may be explained by the absence or 
presence of an as yet unidentified CD95L-processing metalloprotease. 
The aggravation of SLE by cl-CD95L thus appears to involve a two-step mechanism. First, 
selective recruitment of Th17 and Th1-cell, conserved in both mouse and humans, occurs at 
the expense of Treg cell recruitment and may advance inflammation in damaged SLE organs. 
Second, Th17 cells exposed to cl-CD95L upregulate their expression of the PSGL-1 adhesion 
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molecule. PSGL-1 not only promotes tethering of lymphocytes to endothelial cells and 
subsequent rolling, but also its high expression levels in T-cells provoke the secretion of 
effector cytokines (Baaten et al., 2013). 
Of interest, the cellular balance between ceramide (apoptotic) and S1P (survival) is crucial for 
cell fate (Cuvillier et al., 1996) and although the interplay between CD95 and ceramide 
synthesis is well-known and contributes to the induction of the cell death program (Cifone et 
al., 1994), our findings provide evidence that a molecular link also exists between CD95 
stimulation and activation of the S1P signaling pathway. Furthermore, activation of the S1P 
signaling pathway by cl-CD95L furnishes a molecular mechanism that can explain how T-
cells and more specifically Th17 cells migrate in presence of this naturally-processed ligand. 
Based on our study and recent data from Yosef and colleagues that showed using 
transcriptional profiling, a role for CD95 in Th17 differentiation (Yosef et al., 2013), we 
conclude that CD95L/CD95 signals play a pivotal role in autoimmunity and not only through 
its canonical apoptotic role. 
We employed complementary approaches to reveal that CD95-CID directly interacts with the 
PLCγ1-SH3 domain to implement a Ca2+ signal. Linker for activation of T-cells (LAT) is a 
critical adaptor molecule required for TCR-mediated Ca2+ responses. Upon TCR engagement, 
LAT recruits PLCγ1 via its SH2 domains (Zhang et al., 2000). CD95 and TCR therefore 
recruit PLCγ1 through different domains, and TAT-CID failed to inhibit TCR-mediated Ca2+ 
signaling in the current study. Moreover, blockade of CD95-mediated Ca2+ signaling by TAT-
CID not only prevented selective recruitment of Th17 cells to the peritoneal cavity of cl-
CD95-injected mice, but also lessened clinical symptoms in heterozygous lpr mice. These 
observations implicate TAT-CID as an attractive therapeutic molecule with high selectivity 
toward the CD95-mediated Ca2+ signaling pathway. 
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Cl-CD95L induces the transient (within minutes) recruitment of PLCγ1. The CD95 domain 
encompassing aa 175–210 has never been crystallized, probably because this region 
corresponds to an intrinsically disordered region (IDR) that lacks a unique three-dimensional 
structure. We conducted several molecular dynamics experiments to confirm that this peptide 
has very low propensity, if any, for folding (Fig. S7C-D). Numerous examples are now 
documented of transient protein/protein interactions involving IDRs, indicating the importance 
of IDRs in allowing proteins to briefly associate with a large number of partners so as to 
dynamically modulate cell signaling (Cumberworth et al., 2013). This molecular feature is 
consistent with the CD95-CID-mediated induction of a rapid and transient Ca2+ response to 
promote cell migration via the MISC formation. 
A recent phase I/II clinical trial demonstrated that a decoy CD95 receptor, APG101, could 
impede CD95/CD95L interaction and benefited patients suffering from glioblastoma 
(Tuettenberg et al., 2012). Although APG101 may be of short-term therapeutic benefit to 
lupus patients, its inability to discriminate between the anti-tumor/infectious (i.e., apoptotic 
signaling) and pro-inflammatory actions of CD95 may lead to unexpected adverse events. 
As we have found that inhibiting the CD95-mediated Ca2+ response does not interfere with 
apoptotic signaling, we propose that selective blockade of CD95-mediated Ca2+ signaling 
might open new therapeutic avenues for SLE treatment in the future. Moreover, given the 
selective effect of cl-CD95L on Th17 cell recruitment, we also propose that downregulating 
Ca2+ signaling may lessen the inflammatory activity of Th17 cells in other chronic 
inflammatory disorders. 
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MATERIALS & METHODS 
Antibodies and other reagents 
See supporting materials and methods. 
Plasmids and Constructs 
All constructs and primer pairs used are described in supporting materials and methods. 
T Cell subset isolation 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy-coat by density gradient 
using lymphocyte separation medium (Eurobio, Les Ulis, France). PBMCs were then 
subjected to selection using a cocktail of antibody-coated magnetic beads: 
CCR6+CXCR3−CD4+ cells (Th17 cells) were sorted with Human Th17 Enrichment kit 
(STEMCELL Technologies, Grenoble, France) and CD4+CD25+CD127- Treg cells were 
isolated with MACS column (Miltenyi Biotec, Paris, France). 
Transcriptomic analysis 
Isolated Th17 and Treg cells from two healthy donors were treated with or without 100ng/ml 
of cl-CD95L for 8h. Total RNA was extracted using the Nucleospin RNA XS kit (Macherey-
Nagel, Hoerdt, France), quality was assessed using the RNA6000 nano chip (Agilent, Les 
Ulis, France). For each condition, 9 ng of RNA was reverse transcribed using the Ovation 
PicoSL WTA System V2 (Nugen, Leek, The Netherlands). Fragmented cDNAs were 
hybridized to GeneChip Human Gene 2.0 ST microarrays (Affymetrix, High Wycombe, UK). 
Then chips were scanned on a GeneChip Scanner 3000 7G (Affymetrix). Raw data and 
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quality controls metrics were generated from scanned images using the Expression Console 
software (Affymetrix). 
Probes were mapped using Brainarray V20 CDF files  
(http://brainarray.mbni.med.umich.edu/) and RMA normalized using R software. Raw and 
normalized data are deposited to the GEO database (accession id GSE78909). Statistical 
analyses were performed with Partek Genomics Suite (Partek Inc., St. Louis, MO, USA), a p-
value ≤0,05 was considered significant. Pathway enrichment analyses were generated with 
Ingenuity Pathway Analysis (QIAGEN, Redwood City, CA, USA). 
MRL/lpr mouse treatment 
MRL/lpr were obtained from the Jackson Laboratory and backcrossed onto a MRL 
background. Females mice (n=8/group) were intraperitoneally administrated with either TAT-
CID or TAT-Ctrl peptides (40mg/kg) starting at 8 weeks of age, twice weekly for 5 weeks. 
After re-stimulation of CD4+ cell populations with anti-CD3, cell culture supernatants were 
dosed for IL-17A and IFN-γ by ELISA, qPCR analysis of purified cell population was also 
performed as above mentioned. Kidneys were fixed into 4% PFA o/n prior to moving to 
ethanol, sectioning and staining. Scoring was conducted by an individual blind to the 
objective/treatments within the study as per (Kikawada et al., 2003). FITC-conjugated rabbit 
anti-C3 polyclonal antibody (Dako) and nuclei (DAPI, sigma-aldrich) staining were performed 
on frozen kidney sections and analyzed using NIKON Ni-E (magnification ×200). C3 
accumulation in kidneys was assessed by densitometric analysis of ten different fields using 
NIS-Elements AR Analysis software. 
Transendothelial migration of activated T lymphocytes 
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Membranes (3 pm pore size) of a Boyden chamber were hydrated in sterile D-PBS 
(Millipore, Molsheim, France). Activated T-lymphocytes (106) were added to the top 
chamber on a confluent monolayer of HUVEC in a low serum (1%)-containing medium. The 
bottom chamber was filled with low serum (1%)-containing medium in presence or absence 
of 100 ng/ml of cl-CD95L. In experiments using human sera, 500pl of serum from either 
healthy donors or SLE patients was added to the lower chamber. Cells were cultured for 24 h 
at 37°C in a 5% CO2, humidified incubator. Transmigrated cells were counted in the lower 
reservoir by flow cytometry using a standard of 2.5x104 fluorescent beads (Flow-count, 
Beckman Coulter). 
Additional information in supporting Materials and Methods 
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FIGURES 
Figure 1. Serum CD95L in SLE patients induces transmigration of T lymphocytes. A. 
Soluble CD95L levels were measured in serum from newly diagnosed SLE patients (n=34) 
and healthy donors (n=8) via ELISA (Student’s t-test). B. CD95L in SLE serum was 
fractionated by size-exclusion column chromatography and measured via ELISA. Inset: 
CD95L was immunoprecipitated from gel filtration fractions 40–46 and 76–78 and subjected 
to Western blotting. Image presented is representative of gel filtration analysis of four 
different patients. C. CD95L and IL-17 staining in inflamed skin samples from lupus patients 
or healthy mastectomy subjects. Numbers represent different patients. Space bar = 100 μm. D. 
CD95L, CD31, CD4 and IL-17 staining in inflamed skin samples from a SLE patient. V, 
represents endothelial vessel, arrowheads identify marker-expressing cells. E. Densitometric 
analysis of CD95L and IL-17 staining in different patients. F. Transmigration of human T-cell 
subpopulations in the presence of serum from SLE patients or healthy donors. G. Th17 T-cell 
transmigration in the presence of SLE serum containing the indicated concentrations of CD95-
Fc. Undifferentiated Th0 T-cells served as controls. Data represent means ± the standard 
deviation (SD) of 5 individual serum donors. H. CD4+ T-cell transmigration with or without 
cl-CD95L (100 ng/mL). Data represent means ± SD of three independent experiments. I. Treg 
and Th17 cell transmigration with or without cl-CD95L (100 ng/mL) Data represent means ± 
SD of three independent experiments. (two-way ANOVA). 
Figure 2. Transcriptomic signature in human Th17 and Treg cells stimulated with cl-
CD95L. A Venn diagram comparing the genes differentially expressed between untreated and 
cl-CD95L-treated T-cell subsets. B. Heatmap depicting the relative fold change in the amount 
of transcripts significantly (p ≤ 0.05) and differentially expressed between Th17 and Treg cells 
stimulated with cl-CD95L (100 ng/mL). Data for each experimental group (n = 2 per 
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condition) are shown. The scale bar indicates fold change. C. Pathway enrichment analysis of 
genes whose expression is significantly modulated by cl-CD95L in Th17 and Treg cells, and 
associated P values. D. Left panel: endothelial transmigration of human Th17 and Treg cells 
was evaluated in presence or absence of cl-CD95L (100 ng/mL) using Boyden chamber. Right 
panel: Th17 cells were pre-treated with FTY720 (1 μM), TY-52156 (10 μM), VPC-23019 (10 
μM), W146 (1 μM) or CAY-1044 (1 μM) and then exposed to cl-CD95L (100 ng/mL) and 
endothelial transmigration was evaluated using Boyden chamber. Data represent means ± SD 
of three independent experiments. 
Figure 3. Cl-CD95L is a chemoattractant for Th17 cells in vivo. Mice received a single 
injection of cl-CD95L (200 ng/animal) or vehicle and were sequentially sampled. A. T cell 
populations were obtained from tissues or peritoneal cavity washes. Cells were then 
restimulated in the presence of PMA/Ionomycin for 4 hours and then analyzed by flow 
cytometry. Cells were identified as follows; Th1 (CD4+IFN-γ+), Th17 (CD4+IL-17+), and Treg 
(CD4+Foxp3+). Infiltrating cell numbers were calculated. B. 24 hours post injection, ratios of 
Th17/Th1 cells per organ were determined. Data represent two independent experiments, 
using 6 mice/group, displaying means ±SEM. 
Figure 4. CD95 induces a DD-independent Ca2+ response. A. CEM T-cells were stimulated 
with cl-CD95L (100 ng/mL). Cells were lyzed and CD95 was immunoprecipitated. The protein 
complex was resolved by SDS-PAGE, and subjected to Western blotting. Total lysates served as 
controls. B indicates a treatment with beads alone. Data are representative of three independent 
experiments. B. Left panel: Th17 cells from peripheral blood were stimulated with cl-CD95L 
(100 ng/mL) for indicated times. PLA was performed using anti-CD95 and anti-PLCγ1 mAbs. 
Nuclei were stained in blue (DAPI). Red dots were observed when the 
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distance between anti-CD95 and anti-PLCγ1 mAbs was close (≈16 nm). Right panels: Red 
dots were counted in 200 cells taken from different fields. Data represent means ±SD of three 
independent experiments. C. Schematic diagram of CD95 constructs. D. CEM-IRC cells 
expressing GFP alone or the GFP-fused CD95 constructs shown in (C) were loaded with the 
Ca2+ probe, Fluo2-AM (1 μM). Cells were stimulated with cl-CD95L (100 ng/mL; arrow), and 
the intracellular calcium concentration ([Ca2+]i) was monitored. Data are given as means ± SD 
of three independently performed experiments on n=20 cells. E. HEK cells transfected with 
the indicated constructs were stimulated with CD95L (100 ng/mL) for indicated times. The 
CD95 protein complex was immunoprecipitated from cell lysates and subjected to Western 
blotting, as indicated. Total lysates served as controls. B indicates a treatment with beads 
alone. Data are representative of three independent experiments. F. Activated PBLs were pre-
incubated for 1 h with TAT-control or TAT-CID (10 μM), and stimulated with cl-CD95L (100 
ng/mL) for the indicated times. The CD95 protein complex was immunoprecipitated from cell 
lysates and subjected to Western blotting, as indicated. Total lysates served as controls. B 
indicates a treatment with beads alone. Data are representative of three independent 
experiments. G. Activated PBLs from healthy donors were loaded with FuraPE3-AM (1 µM) 
and pre-treated for 1 h with TAT-control or TAT-CID (10 μM). Cells were stimulated with cl-
CD95L (100 ng/mL; arrow). Data represent means ± the SD. 
Figure 5. CID interacts with the SH3 domain of PLCγ1. A. The intracellular region of 
CD95 (aa 175–319) fused to F2 was co-transfected into HEK cells with the indicated domains 
of PLCγ1 fused to F1. Refolding of the luciferase and reconstitution of enzyme activity 
revealed protein/protein interactions. Data represent means ± SD of three independent 
experiments. B. The PLCγ1-SH3 domain (aa 790–851) fused to F1 was co-transfected into 
HEK cells with the indicated regions of CD95 fused to F2, and luminescence was assessed. 
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Data represent means ± SD of three independent experiments. C. CD95-CID-F2 and PLCγ1-
SH3-F1 were co-transfected into HEK cells. Transfected cells were pre-incubated for 1 h with 
TAT-control (50 μM) or TAT-CID (50 and 10 μM), and luminescence was measured. D. 
Predicted interaction between CID and PLCγ1. TCRKHRK is the optimal aa sequence within 
CD95-CID for interaction with PLCγ1-SH3. E. Indicated cells were pre-incubated for 1 h with 
TAT-control, TAT-CID, TAT-CID-N, or TAT-CID-C (10 μM) and then stimulated with cl-
CD95L (100 ng/mL). [Ca2+]CYT was assessed in FuraPE3-AM (1 µM)-loaded cells. Data 
represent means ± the SD of 3 independent experiments. 
Figure 6. TAT-CID alters immunological parameters in lupus-prone mice. A. 
Transmigration of mouse Th17 cells was monitored with the indicated concentrations of TAT-
CID. B–D. C57BL/6 mice were injected with TAT-control or TAT-CID (40 mg/kg) 2 hours 
prior to intraperitoneal injection of cl-CD95L (200 ng) or vehicle. Animals were examined 24 
hours after cl-CD95L injection. B. Total cell counts are shown in the peritoneal cavity. C. 
PECs were subjected to magnetic bead separation to identify the percentage of infiltrating 
CD4+CD62L− (activated) T-cells. D. IL-17A concentrations in the peritoneal cavity were 
measured via ELISA (two-way ANOVA). Data in B-D represent two independent experiments 
performed with 6 mice/group. Data are means ±SEM. E–I. MRL/lpr+/− mice received either 
TAT-CID or TAT-control for 5 weeks. E. Ratios spleen/body weights of individual animals 
were measured upon completion of the experimental protocol and compared to those of age 
matched MRL and homozygous MRL/Lpr mice. F. Total cell number in the spleen is shown. 
G. Cellular composition of the spleen was determined in regard to CD4+CD62L− T-cell 
number. H. mRNA expression levels of il-23r, ccr6, and ror-γt in cells from (C). I. Isolated T-
cells from (G) were re-stimulated with anti-CD3 mAb for 72 h. IL-17A was then quantified by 
ELISA (unpaired Student’s t-test). 
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Figure 7. TAT-CID alleviates clinical disease in lupus-prone mice. MRL/lpr+/− mice 
received either TAT-CID or TAT-control twice weekly for 5 weeks. Kidneys were fixed, 
sectioned, and stained with hematoxylin and eosin. All images were captured at 40× 
magnification. A. Representative section of the vasculature (V) in a TAT-CID-treated mouse, 
with no obvious cellular infiltrate surrounding the border (delineated by the dashed black 
line). B. Cellular infiltrate surrounding the vasculature (V) in a TAT-control-treated mouse, 
with multiple cell layers observed adjacent to the vasculature border (dashed black line). C. 
Vascular infiltrate scores were calculated for the kidneys in TAT-CID- and TAT-control-
treated mice. Data represent means ± SD (n = 8 mice/group; one-way ANOVA). D. Kidney 
tissue showing normal glomeruli (arrow) and an adjacent tubule in TAT-CID-treated mice. E. 
Kidney tissue showing pathological modifications (arrows) to the glomeruli in TAT-control-
treated mice. All images were captured at 20X (B; scale bar = 250μm) or 40X (A, D, E; scale 
bar = 150μm) magnification. F. Glomerular damage scores were calculated for each kidney in 
TAT-CID- and TAT-control-treated mice. Data represent means ± SD (n = 8 mice/group; *** 
P < 0.001; t-Test). G. C3 complement accumulation in kidneys of TAT-CID and TAT-control-
treated MRL/Lpr+/- mice was assessed by microscopy. Inset: pictures of nucleus (DAPI) and 
C3 staining in mouse kidneys. H. Serum creatinine (upper panel) and urea (lower panel) were 
measured. I. Anti-dsDNA IgG1 levels were determined by ELISA. Data represent means ± 
SD (n = 8 mice/group; t-Test). J. Immunohistochemistry staining of IFN-y or IL-17. Cytokine 
positive cells were counted in treated kidneys. 
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SUPPORTING FIGURE LEGENDS 
Supporting Figure 1. Endothelial transmigration of Th17 CD4+ T lymphocytes. A. The 
expression of CD95L or IL17 was analyzed by immunohistochemistry in inflamed skin from 
patients affected by lupus. Numbers represent different patients. B. HUVECs were incubated 
in the presence or absence of cl-CD95L (100 ng/mL) for 24 h. Next, the cells were detached 
using an EDTA-containing solution and stained with the indicated mAbs. The presence of the 
different proteins was detected by flow cytometry using a PE-conjugated secondary anti-
mouse antibody. The histogram is representative of four independent experiments. C. The 
values for each indicated marker (upper panels: PSGL1 and lower panel: LFA-1) represent 
the mean fluorescence intensity (MFI) (± SD) measured by flow cytometry. For each Th 
subset, between 6 and 10 independent experiments were performed. D. Endothelial 
transmigration of human Th1, Th17, or Treg cells was assessed in the presence of 
neutralizing anti-E-selectin (10 µg/mL) antibody. Data were analyzed using two-way 
ANOVA. *P < 0.05 and ***P < 0.001. E. Left panel: Treg and Th17 cells were sorted from 
peripheral blood of healthy donors and the CD95 expression level at the surface of these cells 
was evaluated by flow cytometry. Intermediate panel: Comparison of CD95 Expression in 
different CD4+T cell subsets: Naive CD4+ (CD45RA+CD4+), Memory CD4+ (CD4+CD45RA-
), Th1 (CD4+CXCR3+CCR6-CD45RA-), Th17 (CD4+CXCR3-CCR6+CD45RA-), Treg cells 
(CD4+CD25highFoxP3+). Right panel: CD95 expression was normalized as follows: CD95 
MFI in Th subset or Treg divided by CD95 in naive CD4+T. Wilcoxon paired analysis was 
performed in a set of 20 healthy donors. Histogram plots represent mean ±SD. F. Flow 
cytometry analyses demonstrating the efficiency of Treg (left panels) and Th17 cell (right 
panels) sorting from human peripheral blood. G. Schema of the S1P signaling pathway. In 
red, genes upregulated in Th17 cells stimulated with cl-CD95L. 
2 
Supporting Figure 2. Cl-CD95L is a chemo-attractant for Th17 cells in vivo. Mice 
received a single injection of cl-CD95L (200 ng) or vehicle prior to sacrifice 24 h later. All 
experiments were repeated three times. A, B, C, D, E. CD4+CD62L PECs were purified by 
AutoMACS separation, and RNA was prepared prior to real-time qPCR to assess expression 
levels of (A) IL-17A, (B) IL-23R, (C) CCR6, (D) IFN-y, and (E) FoxP3 mRNA. Data 
represent means ± the SD (n = 6 mice per group; *P < 0.05, **P < 0.01, and ***P < 0.001; 
Student’s t-test). GAPDH, glyceraldehyde 3-phosphate dehydrogenase. 
Supporting Figure 3. Amino acid residues 175–210 of CD95 induce the Ca2+ signaling 
pathway. A. Parental CEM T-cells and their low CD95-expressing counterpart, namely CEM-
IRC (for Ig-CD95L resistant cell) were stimulated with cl-CD95L (100 ng/mL) for indicated 
time points. PLA was performed using anti-CD95 and anti-PLCy1 mAbs. Nuclei are stained in 
blue (DAPI). Red dots were observed when the distance between anti-CD95 and anti-PLCy1 
mAbs was close (≈16 nm). Inset: The expression level of CD95 was evaluated in Parental 
CEM and CEM-IRC cells by flow cytometry. B. Parental Jurkat T-cells and their PLC-y1-
deficient and PLC-y1-reconstituted counterparts were loaded with the Ca2+ probe, FuraPE3-
AM (1 tM), prior to stimulation with cl-CD95L (100 ng/mL; black arrow). Ratio images 
(F340/F380, R) were taken every 10 s and normalized against pre-stimulated values (R0). Data 
represent the mean ± SD of R/R0. Inset: PLCy1-deficient Jurkat cells or their reconstituted 
counterparts were lysed, and the expression of PLCy1 and CD95 was evaluated by 
immunoblotting. Tubulin was used as a loading control. C. Parental Jurkat cells (A3) and their 
counterparts lacking FADD or caspase-8 were treated with the indicated concentrations of 
cytotoxic IgCD95L for 20 h. Cell death was assessed using MTT assay. D. Indicated cells were 
loaded with the Ca2+ probe FuraPE3-AM (1 tM) and then stimulated with cl-CD95L 
3 
(100 ng/mL). Data were analyzed as described in B. Inset: Parental Jurkat cells (A3) or their 
counterparts lacking either FADD or caspase-8 were lysed, and the expression levels of 
CD95, FADD, and caspase-8 were examined by immunoblotting. E. The levels of CD95 
expression at the cell surface of CEM-IRC clones reconstituted with the indicated CD95 
constructs were evaluated by flow cytometry. Data are representative of three independent 
experiments. F. Cells described in E were treated with the indicated concentrations of 
IgCD95L for 20 h. Cell death was assessed using MTT assay. G. HEK cells were co-
transfected with the GFP-fused CD95 constructs and wild-type PLCγ1. Twenty-four hours 
after transfection, the levels of CD95 expression were evaluated by flow cytometry. H. Left 
panel: HEK cells were co-transfected with PLCγ1 and mCherry or mCherry-CID. After 24 h, 
cells were lysed and PLCγ1 was immunoprecipitated. The immune complex was resolved by 
SDS-PAGE and subjected to immunoblot analysis as indicated. Total lysates were loaded as a 
control. Right panel: HEK cells were co-transfected with PLCγ1 and CID-mCherry or 
mCherry alone. After 24 h, cells were stimulated in the presence or absence of CD95L (100 
ng/mL), and CD95 was immunoprecipitated. The immune complex was resolved by SDS-
PAGE and immunoblotted as indicated. Total lysates were loaded as a control. 
Supporting Figure 4. Cell-penetrating TAT-CID peptide inhibits the CD95-induced Ca2+ 
response without affecting the apoptotic signaling pathway. A. Protein sequences of TAT-
CID and TAT-control. B. The leukemic T-cell line CEM was pre-incubated for 1 h with 10 µM 
of TAT-control or TAT-CID and then stimulated in the presence or absence of cl-CD95L (100 
ng/mL) for the indicated times. Cells were lysed and CD95 was immunoprecipitated. The 
immune complex was resolved by SDS-PAGE and immunoblotted as indicated. Total lysates 
were loaded as a control. C. Jurkat and CEM cells were loaded with FuraPE3-AM (1 µM), pre-
treated for 1 h with 10 µM TAT-control or TAT-CID, and then stimulated with 100 
4 
ng/mL of cl-CD95L (black arrow). Ratio images were taken every 10 s and normalized against 
pre-stimulated values. D. Activated PBLs were pre-incubated for 1 h with 10 jiM TAT-control 
or TAT-CID and then stimulated in the presence or absence of cl-CD95L (100 ng/mL) for the 
indicated times. Cells were then lysed, and 100 jig of protein was resolved by SDS-PAGE and 
immunoblotted as indicated. Total Akt served as a loading control. E. The indicated cells were 
pre-incubated for 1 h with a non-toxic dose of TAT-control or TAT-CID (10 jiM), and cell 
death was assessed in an MTT assay. 
Supporting Figure 5. CID-CD95 directly interacts with SH3-PLCγ1 domain. A. The 
Renilla luciferase enzyme was divided into amino-terminal and carboxy-terminal fragments (F1 
and F2, respectively). B. Human PLC71 domains. PH, pleckstrin homology domain; cat, 
catalytic domain; and SH, src homology domain. C. HEK cells were transfected with indicated 
constructs. After 24 h, cells were lysed, and the expression levels of the different constructs 
were examined by immunoblotting using an anti-luciferase mAb recognizing the amino-
terminal region of luciferase (MAB4410, Millipore, France). D. HEK cells were treated as in C 
and the expression levels of the indicated constructs were examined by immunoblotting using 
an anti-luciferase mAb recognizing the carboxy-terminal region of luciferase (MAB4400, 
Millipore). E. Each amino acid in CID sequence was replaced by alanine (alanine scanning) and 
all constructs were co-transfected with SH3-PLC71 in HEK cells. For each co-transfection, 
luminescence was assessed and a ratio was calculated as follows: (luminescence for mutated 
construct/ luminescence for wild type CID) x 100). For each condition, this value was next 
multiplied by the relative expression level of CID-F2 and SH3-PLC71-F1, evaluated by 
densitometric analysis of proteins as follows: ((densitometric value of mutated CID-F2 
construct/ densitometric value of wild type CID-F2) x (densitometric value of co-transfected 
SH3-PLC71-F1/ densitometric value of SH3-PLC71-F1 
5 
co-transfected with wild type CID)). F. CID sequence of wild type CD95 (TCRKHRK) 
underwent double (TCAAHRK) or triple (TCAAHRA) mutations and these constructs were 
transiently transfected in HEK cells. Calcium signal was assessed using fluo2-AM (1 µM). 
Cells were stimulated with cl-CD95L (100 ng/mL; arrow), and the intracellular calcium 
concentration ([Ca2+]i) was monitored by measuring the F/F0 ratio (relative cytoplasmic 
calcium concentration ([Ca2+]CYT)). G. Sequences of cell-penetrating peptides CID-N and CID-
C. H-I-J. Indicated cells were loaded with the Ca2+ probe FuraPE3-AM (1 µM). Ratio images 
were taken every 10 s and normalized against pre-stimulated values. H. The anti-CD3 mAb 
OKT3 (1 µg/mL) evokes a PLCγ1-dependent Ca2+ response in Jurkat cells. I. Pre-incubation of 
Jurkat T-cells for 1 h with 10 µM TAT-CID or TAT-control had no effect on the CD3-induced 
Ca2+ response. J. The PLCβ-driven Ca2+ response induced by carbachol (10 µM) in Jurkat cells 
was not affected by TAT-CID pre-treatment (10 µM for 1 h). 
Supporting Figure 6. A cell-penetrating murine CID inhibits the CD95-mediated Ca2+ 
response in murine T-cells. A. Mouse and human CD95 sequences were aligned using 
ClustalW2 (Larkin et al., 2007). B. Inset: CEM-IRC cells were reconstituted with murine 
CD95, a clone was selected, and its CD95 expression level was evaluated by flow cytometry. 
The sensitivity of murine CD95-expressing CEM-IRC to the cytotoxic CD95L, IgCD95L, was 
assessed using MTT assay. C. The cells were loaded with the Ca2+ probe FuraPE3-AM (1 
µM). Ratio images were taken every 10 s and normalized against pre-stimulated values. Pre-
incubation of murine CD95-expressing CEM-IRC T-cells with 10 µM TAT-mCID for 1 h 
inhibited the CD95-mediated Ca2+ response, whereas pre-incubation with TAT-hCID did not. 
D. The murine CID sequence fused to the cell-penetrating peptide TAT. E. Activated murine 
PBLs were loaded with the Ca2+ probe FuraPE3-AM (1 µM). Ratio images were taken every 
10 s and normalized against pre-stimulated values. Pre-incubation of activated murine PBLs 
6 
with 10 µM TAT-mCID for 1 h inhibited the CD95-mediated Ca2+ response, whereas pre-
incubation with TAT-hCID did not. F-G-H. 8-week old MRL/lpr+/- mice were administered 
with either TAT-CID or TAT-control peptide twice weekly for five weeks. Upon completion 
of the treatment, total body (F) and organ weight (G) were assessed. H. B-cell composition of 
the spleen was evaluated. 
Supporting Figure 7. Infiltrating CD8 T-cells in skin lesions of lupus patients and 
computer modeling of CID. A. Expression of CD95L and CD8 was assessed by 
immunohistochemistry. The numbers represent the different patients. B. Densitometric analysis 
of the CD8 and CD95L staining depicted in A revealed no inverse correlation between CD8 and 
CD95L expression levels in skins of SLE patients. C. Observed backbone hydrogen bonds 
between pairs of residues (% as a function of the simulation time). Counting main chain 
hydrogen bonds during the 40 ns molecular dynamics analysis revealed that these interactions 
were rare. D. Dynamics of the peptide structures. RMSD and radius of gyration suggest that the 
system was stable, with no detectable compression of the peptide. This means that no stable 
secondary structures occurred. The presence of short structural elements was noticed from time-
to-time, e.g., in the middle of the peptide at 5 ns and at the COOH-terminus at 13, 20, 30, and 
37 ns. These folds correspond to discrete events, and the peptide did not adopt a stable 3D 
structure (the small α-helices have a short half-life and are quickly broken). 
7 
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Patients and Ethics Statement 
SLE patients fulfilled four or more of the 1982 revised ACR criteria for the disease. All 
clinical investigations were conducted according to the principles expressed in the 
Declaration of Helsinki. Blood was sampled from patients diagnosed with SLE after written 
consent was obtained from each individual. This study was approved by institutional review 
board at the Centre Hospitalier Universitaire de Bordeaux. Animal experiments were 
conducted under UK Home Office licence number 40/3412 at the University of Nottingham 
and subject to local ethical review. 
Antibodies and other reagents 
PHA, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), protease and 
phosphatase inhibitors were purchased from Sigma-Aldrich (L’Isle-d’Abeau-Chesnes, 
France). Anti-CD95L mAb was from Cell Signaling Technology (Boston, MA, USA). 
Recombinant IL-2 was obtained from PeproTech Inc. (Rocky Hill, NJ, USA). Anti-PLCγ1 
was purchased from Millipore (St Quentin en Yvelines, France). Anti-CD95 mAbs (APO1-3) 
came from Enzo Life Sciences (Villeurbanne). PE-conjugated anti-human CD95 (DX2) 
mAb, anti-human FADD mAb (clone1), neutralizing anti-CD95L mAb (Nok1) were 
provided by BD Biosciences (Le Pont de Claix, France). Anti-Fas (C-20) mAbs were from 
Santa Cruz Biotechnology (Heidelberg, Germany). CD95-Fc, neutralizing anti-ICAM-1 and 
E-selectin antibodies were from R&D Systems. Anti-CD4 (VIT4) and anti-CD25 (4E3) 
mAbs were from Miltenyi Biotec and anti-CCR6 (G034E3) and anti–CXCR3 (G025H7) 
were purchased from Biolegend. Anti-CD25 (4E3) and anti-Foxp3 (236AE7) mAbs were 
from eBiosciences (Paris, France). 
Plasmids and Constructs 
GFP-tagged human CD95 (hCD95) constructs were obtained by PCR and inserted in frame 
between the Nhe1 and EcoR1 restriction sites of the pEGFP-N1plasmid (Clontech). Note that 
for all CD95 constructs the numbering takes into consideration the subtraction of the 16 
amino-acid signal peptide sequence The primer pairs used are as follow: forward 
GCTAGCGACGCTTCTGGGGAGTGA; reverse (1-319) 
CTCGAGGACCAAGCTTTGGATTTC; (1-303) 
CTCGAGAGTAATGTCCTTGAGGATGAT; (1-210) 
CTCGAGATCAGATAAATTTATTGCCACTGTTTC; (1-175) 
CTCGAGCTTCACCCAAACAATTAGTGG. Substitution of the cystein at position 183 by a 
valine in hCD95(1-210) was performed using the Quickchange Lightning Site-directed 
Mutagenesis kit (Agilent Technologies, Les Ulis, France) according to manufacturer 
instructions and using the primer pair forward  
GAGAAAGGAAGTACAGAAAACAGTGAGAAAGCACAGAAAGGAAAACC and 
reverse GGTTTTCCTTTCTGTGCTTTCTCACTGTTTTCTGTACTTCCTTTCTC. The CID-
mCHERRY construct was obtained by PCR amplifying the hCD95 sequence coding for 
the residues 175 to 210 using a forward primer  
GAATTCATCGATATGAAGAGAAAGGAAGTACAGAAAACATGC adding in 5’ an 
EcoR1 cloning site, an optimal Kozak sequence and a starting methionine in combination 
with the reverse primer  
CTCGAGAGCACCAGCACCAGCACCAGCACCATCAGATAAATTTATTGCCACTGTT 
TC coding for a 8 amino acid linker (GAGAGAGA) and a BamH1 cloning site. The resulting 
fragment was inserted between the EcoR1 and BamH1 restriction sites of a pmCHERRY-N1 
vector. Mouse full length CD95 (mCD95) was kindly provided by Dr Pascal Schneider 
(Universite de Lausanne, Lausanne, Switzerland). The mCD95 sequence lacking the signal 
peptide (SP - residues 1-21) was amplified by PCR using the following primer pair: forward 
GGATCCCAAGGTACTAATAGCATCTCCGAGAG and reverse  
GAATTCTCACTCCAGACATTGTCCTTCATTTTC. After digestion by BamHI/EcoRI, the 
amplicon was inserted into pcDNA3.1(+) vector in frame with SP sequence of the influenza 
virus hemagglutinin protein from (MAIIYLILLFTAVRG) followed by a flag tag sequence 
and a 6 amino acid linker (GPGQVQ). The pTriEx-4 vector encoding for Myc-tagged full-
length human PLCγ1 was a gift from Dr. Matilda Katan (Chester Beatty Laboratories, The 
Institute of Cancer Research, London, United Kingdom). Plasmids coding for full length 
CD95L and the secreted IgCD95L have been described elsewhere (Tauzin et al., 2011). All 
constructs were validated by sequencing on both strands (GATC Biotech, Constance, 
Germany). 
PKAReg.hRluc-F[1].pcDNA3.1(+) and PKACat.hRluc-F(2).pcDNA3.1(+) (Stefan et al., 
2007) were a kind gift from Dr S. W. Michnick (Université de Montréal). PKAReg.hRluc-
F[1].pcDNA3.1(+) was cleaved by EcoR1 and BspEI to eliminate the PKA sequence and 
insert the following linker  
GAATTCGCGGCCGCATCGATGGTGGCGGTGGCTCTGGAGGTGGTGGGTCCTCCGG 
A to generate hRluc-F[1].pcDNA3.1(+). The different PLCγ1 domains were amplified by 
PCR from the pTriEx-4 vector encoding Myc-tagged full-length human PLCγ1, with the 
following set of primers: PLCγ1 (1-467) 
(TAGTCCAGTGTGGTGGAATTCATGGCGGGCGCCGCGTCCCCT and  
TCCAGAGCCACCGCCACCATCGATAGCCAGCTTCTTGTGCTTGATG); PLCγ1 (550-
667) (TAGTCCAGTGTGGTGGAATTCATGTGGTTCCATGGGAAGCTAGGGGC and 
TCCAGAGCCACCGCCACCATCGATGACAGGCTCTGAAAGTCGCATCTC); PLCγ1 
(668-756) (TAGTCCAGTGTGGTGGAATTCATGTGGTACCACGCGAGCCTGACCAG 
and TCCAGAGCCACCGCCACCATCGATGATGGGATAGCGCAGCTTCATCTTG); 
PLCγ1 (790-851) 
(TAGTCCAGTGTGGTGGAATTCATGCCAACTTTCAAGTGTGCAGTC and 
TCCAGAGCCACCGCCACCATCGATGTTGACCATCTCTTCCACGTAG); PLCγ1 (952-
1290) (TAGTCCAGTGTGGTGGAATTCATGGAGCTCTCTGAACTTGTCGTCTAC- and 
TCCAGAGCCACCGCCACCATCGATGAGGCGGTTGTCTCCATTGAC) and inserted in 
hRluc-F[1].pcDNA3.1(+) using Gibson assembly protocol (NEB, Ipswich, MA, USA). In 
parallel, PKACat.hRluc-F(2).pcDNA3.1(+) was double digested by EcoRI/ClaI to eliminate 
the PKA sequence and replace it using Gibson assembly, by amplicons coding for CD95-CID 
(amino acid residues 175 to 210) 
(TAGTCCAGTGTGGTGGAATTCATGAAGAGAAAGGAAGTACAGAAAAC and  
TCCAGAGCCACCGCCACCATCGATATCAGATAAATTTATTGCCAC), CD95-DD 
(amino acid residues 211 to 303) 
(TAGTCCAGTGTGGTGGAATTCATGGTTGACTTGAGTAAATATATC and 
TCCAGAGCCACCGCCACCATCGATAGTAATGTCCTTGAGGATGAT) CD95 
intracellular domain (amino acid residues 175 to 319) 
(TAGTCCAGTGTGGTGGAATTCATGAAGAGAAAGGAAGTACAGAAAAC and  
TCCAGAGCCACCGCCACC ATCGAT GACCAAGCTTTGGATTTCATT). All primers 
were purchased from Eurogentec (Liège, Belgium). Constructs were validated by DNA 
sequencing (GATC Biotech, Germany). Alanine scanning experiments were described in 
supporting materials and methods. 
Renilla luciferase-based protein fragment complementation assay 
HEK293T cells were electroporated with 5 jig of DNA using BTM-830 electroporation 
generator (BTX Instrument Division, Harvard Apparatus) with 10 jig of DNA. Transfected 
T Cell subset isolation (Th17 and Treg cells) 
cells were cultured for 24 hrs prior to protein complementation assay analyses as previously 
described (Stefan et al., 2007). Briefly, transfected cells (106) were washed, resuspended in 
100 pl PBS and deposited in OptiPlate-96 (PerkinElmer, Waltham, MA, USA). 
Coelenterazine-h (5 µM, Sigma) was injected to each well and renilla luciferase activity was 
monitored for the first 10 seconds using Infinite200Pro (Tecan, Männedorf, Switzerland). 
Cell lines and peripheral blood lymphocytes 
All cells were purchased from ATCC (Molsheim Cedex, France). The T-cell lines CEM, H9 
and Jurkat were cultured in RPMI supplemented with 8% heat-inactivated FCS (v/v) and 2 
mM L-glutamine at 37 °C in a 5% CO2 incubator. CEM-IRC cells expressing a low amount 
of endogenous CD95 was described in (Beneteau et al., 2007; Beneteau et al., 2008). HEK293 
cells were cultured in DMEM supplemented with 8% heat-inactivated FCS and 2 mM L-
glutamine at 37°C in a 5% CO2 incubator. PBMCs (peripheral blood mononuclear cells) from 
healthy donors were isolated by Ficoll centrifugation, washed twice in PBS. Monocytes were 
removed by a 2 hours adherence step and the naive PBLs (peripheral blood lymphocytes) 
were incubated overnight in RPMI supplemented with 1 pg/ml of PHA. Cells were washed 
extensively and incubated in the culture medium supplemented with 100 units/ml of 
recombinant IL-2 (R&D) for 5 days. Human umbilical vein endothelial cell (HUVEC) (Jaffe 
et al., 1973) were grown in human endothelial serum free medium 200 supplemented with 
LSGS (Low serum growth supplement) (Invitrogen, Cergy Pontoise, France). CEM-IRC cells 
were electroporated using BTM-830 electroporation generator with 10 pg of DNA. 24 hrs 
after electroporation, cells were treated for one week with 1 mg/mL of neomycin and then 
clones were isolated using standard limiting dilution procedures. 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy-coat by density 
gradient using lymphocyte separation medium (Eurobio, Les Ulis, France). PBMCs were 
then subjected to selection using a cocktail of antibody-coated magnetic beads: 
CCR6+CXCR3−CD4+ cells (Th17 cells) were sorted with Human Th17 Enrichment kit 
(STEMCELL Technologies, Grenoble, France) and CD4+CD25+CD127- Treg cells were 
isolated with MACS column (Miltenyi Biotec, Paris, France). Cell sorting efficiency was 
evaluated by FACS. 
Transcriptomic analysis 
Isolated Th17 and Treg cells from two healthy donors were treated with or without 100ng/ml 
of cl-CD95L for 8h. Then, total RNA was extracted using the Nucleospin RNA XS isolation 
kit (Macherey-Nagel, Hoerdt, France) and RNA quality was assessed using the RNA6000 
nano chip kit (Agilent, Les Ulis, France). For each condition, 9 ng of total RNA was reverse 
transcribed using the Ovation PicoSL WTA System V2 (Nugen, Leek, The Netherlands). 
Fragmented cDNAs were then hybridized to GeneChip® Human Gene 2.0 ST microarrays 
(Affymetrix, High Wycombe, UK). After overnight hybridization, chips were washed on the 
fluidic station FS450 and scanned using the GeneChip Scanner 3000 7G (Affymetrix). The 
scanned images were then analyzed with the Expression Console software (Affymetrix) to 
generate raw data and metrics for quality controls. 
Probes were mapped using custom CDF files from Brainarray V20 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/CDF_download.asp ) 
and RMA normalization was performed using R software. Raw data as well as RMA 
normalized data have been deposited to the Gene Expression Omnibus under the accession 
number GSE78909 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78909). 
Statistical analyses were performed using Partek® Genomics Suite® software (Partek Inc., St. 
Louis, MO, USA). Data was filtered based on p-value (p<0,05 was considered significant). 
Pathway enrichment analyses were generated using the Ingenuity Pathway Analysis software 
(QIAGEN Redwood City, CA, USA). 
Immunohistochemistry analysis 
Skin biopsies from lupus patients were embedded in paraffin and cut into 4 μm sections. For 
CD4, CD8 and IL-17 detection, immunohistochemical staining was performed on the 
Discovery Automated IHC stainer using the Ventana OmniMap detection kit (Ventana 
Medical Systems, Tucson, AZ, USA). The slides were rinsed with Ventana tris-based 
Reaction buffer (Roche). Following deparaffination with Ventana EZ Prep solution (Roche) at 
75 °C for 8 min, antigen retrieval was performed using Ventana proprietary chemistry, tris-
based buffer solution CC1 (pH8) antibody, at 95°C to 100°C for 48 min. Endogen peroxidase 
was blocked with Inhibitor-D in 3% H2O2 (Ventana) for 10 min at 37°C. After rinsing, slides 
were incubated at 37°C for 60 min with anti-human IL-17 (Bioss), anti-human CD4 and anti-
human CD8 (Dako), and secondary antibody - OmniMap HRP for 32 min (Roche). Signal 
enhancement was performed using the Ventana ChromoMap Kit Slides (biotin free detection 
system). For CD95L (BD Pharmigen) detection, antigen retrieval was performed using antigen 
unmasking solution pH 9 (Vector) at 95°C for 40 min and endogenous peroxidase was 
blocked using 3% H2O2 in methanol for 15 min. Slides were incubated in 5% BSA for 30 min 
at RT and then stained overnight at 4°C. Tissue sections were incubated with Envision+ 
system HRP-conjugated secondary antibodies for 30 min at RT and labeling was visualized by 
adding liquid DAB+. Sections were counterstained with hematoxylin and mounted with DPX 
mounting medium. Using ImageJ software (IHC toolbox), densitometry analysis was 
undertaken on scanned slides to quantify the level of staining for each target. The mean area 
for each marker was determined. 
Mouse and Human CD4+ T-cell subset generation 
For the generation of murine T-cell subsets, spleens were removed from C57Bl/6 mice and 
single cell suspensions prepared. CD4+CD62L+ naïve cells were isolated using Miltenyi 
Biotec microbeads. Naïve human CD4+ T-cells were prepared using the Miltenyi Biotec naïve 
CD4+ T-cell isolation kit II, which are sorted produced a 99% pure population of 
CD4+CD45RA+ cells. Purified T-cells were cultured in complete IMDM media all with α-
CD3 (1 µg/ml), α-CD28 (2 µg/ml), and as follows; Th1 cells IL-12 (10 ng/ml) with α-IL-4 
(10µg/ml), Th2 cells IL-4 (10 ng/ml) and α-IFN-y (10 µg/ml), Th17 cells Il-6 (10 ng/ml), 
TGF-β1 (2 ng/ml), α-IFN-y (10µg/ml) with α-IL-4 (10 µg/ml), and Tregs IL-2 (10ng/ml) 
TGF-β1 (5ng/ml), α-IFN-y (10µg/ml) and α-IL-4 (10µg/ml). Cells were converted to T-cell 
subsets over five days as outlined above. All cytokines were supplied by PeproTech (London, 
UK). Mouse CD3 (clone 2C11); human CD3 (UCHT1); mouse CD28 (37.51); human CD28 
(CD28.2); mouse IL-4 (11B11); human IL-4 (MP4-25D2); mouse IFN-y (XMG1.2); human 
IFN-y B27 came from BD Pharmigen. 
In vivo administration of cl-CD95L 
Female C57BL/6 mice (Harlan UK) aged between 8-10 weeks were housed in groups of 6 and 
administered IP with 200ng recombinant cl-CD95L or vehicle. Twenty-four hours following 
injection, mice were sacrificed and periteonial cavities were washed with 5ml of 2% FCS in 
sterile D-PBS/, blood smears were prepared, and spleens aseptically collected. Blood smears 
and cytospins of periteonal cells (PECs) were stained with Giemsa and differential counts 
performed. Single cell suspensions of spleens and PECs were prepared, total cell counts 
performed, CD4+CD62- T-cells were isolated with Miltenyi microbeads (as above) and 
number of cells determined by trypan blue exclusion. For experiments where 
IgCD95L was generated as previously described (Tauzin et al., 2011). HEK 293 cells  
animals received TAT-mCID or control peptides, 800μg (40 mg/kg) was injected IP 2hrs prior 
to administration of cl-CD95L. Cell-free peritoneal cavity fluid was retained and used to 
determine the levels of IL-17 and IFN-γ by ELISA (eBiosciences). 
MRL/lpr mouse treatment 
MRL/lpr homozygotes were obtained from the Jackson Laboratory and backcrossed onto a 
MRL background. Females mice (n=8/group) were intraperitoneally administrated with either 
TAT-CID or TAT-Ctrl peptides (40mg/kg) starting at 8 weeks of age, twice weekly for 5 
weeks. After 5 weeks, final body weight was recorded, organs weighed and total spleen and 
CD4+ cell populations sorted as above. After re-stimulation with anti-CD3, cell culture 
supernatants were dosed for IL-17A and IFN-γ by ELISA, qPCR analysis of purified cell 
population was also performed as above mentioned. Total urine protein was measured using a 
BCA assay (Pierce) on bladder contents collected at PM. Briefly, bladder contents were 
collected throughout fine needle aspiration into individual tubes, tubes were centrifuged at 500 
x g for 10 minutes to collect debris. Kidneys were fixed into 4% PFA o/n prior to moving to 
ethanol, sectioning and staining. Scoring was conducted by an individual blind to the 
objective/treatments within the study as per (Kikawada et al., 2003). C3 (rabbit polyclonal 
FITC-conjugated anti-C3 antibody, F0201, Dako) and nuclei (DAPI, sigma-aldrich) staining 
were performed on frozen sections of mouse kidneys and analyzed using fluorescence 
microscopy (NIKON NI-E, magnification × 200). C3 accumulation in kidneys of TAT-CID 
and TAT-control-treated MRL/Lpr+/- mice was assessed by densitometric analysis of ten 
different fields using NIS-Elements AR Analysis software. 
Metalloprotease-cleaved and Ig-fused CD95L production 
maintained in an 8% FCS-containing medium were transfected using by the 
Calcium/Phosphate precipitation method with 3 jig of empty plasmid (as control) or wild type 
CD95L-containing vector. 16 hours after transfection, medium was replaced by OPTI-MEM 
(Invitrogen) supplemented with 2 mM L-glutamine and 5 days later, media containing cleaved 
CD95L and exosome-bound full length CD95L were harvested. Dead cells and debris were 
eliminated through two steps of centrifugation for 15mins at 4500 rpm followed by 
elimination of exosomes by ultracentrifugation at 100,000 x g for 2hrs. 
Size Exclusion Chromatography 
Sera from 4 different SLE patients were filtered through a 0.2 jim filter and then 5 ml was 
resolved using a mid range fractionation S300-HR Sephacryl column (GE Healthcare) 
equilibrated with PBS (pH 7.4). Using an AKTAprime purifier (GE Healthcare), fractions 
were harvested with a flow rate of 0.5 mL/min. Fifty fractions were harvested and analyzed by 
ELISA to quantify CD95L. 
CD95L ELISA 
CD95L ELISA (Diaclone, Besançon, France) was performed to quantify the levels of cleaved-
CD95L present in sera following the manufacturer’s recommendations. 
Immunoprecipitation 
T-cells (5×107 cells per condition) were stimulated with cl-CD95L (100 ng/mL) for indicated 
times at 37°C. Cells were lysed, incubated with 1 ug/mL of anti-CD95 (clone APO1.3) for 15 
min at 4°C and CD95 was immunoprecipitated using protein A/G coated magnetic beads 
(Ademtech, Pessac, France) for 1h. After extensive washing, the immune complex was 
resolved by SDS-PAGE and immunoblotting was performed with indicated antibodies. 
Immunoblot analysis 
Cells were lyzed for 30 minutes at 4°C in lysis buffer (25 mM HEPES pH 7.4, 1% v/v Triton 
X-100, 150 mM NaCl, 2 mM EGTA supplemented with protease inhibitor cocktail (Sigma-
Aldrich)). Protein concentration was determined by the BCA assay (PIERCE, Rockford, IL, 
USA) according to the manufacturer's protocol. Proteins were separated on a 12% SDS-PAGE 
and transferred to a nitrocellulose membrane (GE Healthcare, Buckinghamshire, England). 
The membrane was blocked 15 minutes with TBST (50 mM Tris, 160 mM NaCl, 0.05% v/v 
Tween 20, pH 7.8) containing 5% w/v dried skimmed milk (TBSTM). Membranes were 
incubated with primary antibodies, listed above, overnight at 4°C in TBSTM. The membrane 
was washed in TBST and then incubated in the presence of peroxidase-conjugated anti-rabbit 
or anti-mouse secondary antibodies (SouthernBiotech, Birmingham, Alabama, US) for 45 
minutes. Proteins were visualized with an enhanced chemiluminescence substrate kit as per 
manufacturers instructions (ECL, GE Healthcare). 
Transendothelial migration of activated T lymphocytes 
Membranes (3 μm pore size) of a Boyden chamber were hydrated in sterile D-PBS 
(Millipore, Molsheim, France). Thereafter, activated T-lymphocytes (106) were added to the 
top chamber on a confluent monolayer of HUVEC in a low serum (1%)-containing medium. 
The bottom chamber was filled with low serum (1%)-containing medium in presence or 
absence of 100 ng/ml of cl-CD95L. In experiments using human sera, 500μl of serum from 
either healthy donors or SLE patients was added to the lower chamber. Cells were cultured 
for 24 h at 37°C in a 5% CO2, humidified incubator. Transmigrated cells were counted in the 
lower reservoir by flow cytometry using a standard of 2.5x104 fluorescent beads (Flow-count, 
Beckman Coulter). 
Endothelial cell adhesion assay 
Blocking antibodies were used against E-selectin and ICAM-1 in the CHEMICON® 
endothelial cell adhesion assay (Millipore). Briefly, after activation of the endothelial cell 
layer with TNF-α, anti-mouse Ig controls, anti-E-selectin or anti-ICAM-1 were added at final 
concentrations of 10μg/ml. Thereafter calcein-AM-stained T-cell subsets were added to the 
monolayers for 24 hours and unbound cells are washed. Cell numbers attached to the 
endothelium were assessed using fluorescence readings of excitation at 405nm and emission at 
516nm with reference to a standard curve of stained cells. Human Th17 and Treg cells (3×105 
cells) were pre-treated for 30 min with the selective S1P3 antagonists TY-52156 (TOCRIS 
Biosciences, Lille, France) and CAY-1044, the S1PR1 and S1PR3 inhibitor VPC-23019, the 
S1PR1 antagonist W146 or the S1P1, -3, -4 and -5 agonist FTY-720 and then incubated for 24 
hours with cl-CD95L (100ng/mL). CAY-1044, VPC-23019, W146 and FTY-720 were kindly 
provided by Prof. B. Ségui (Toulouse, France). 
Real-time qPCR 
Single cell suspensions of spleens and PECs were prepared as described above. RNA was 
extracted from CD4 T-cells using phenol/chloroform. cDNA was prepared using the Promega 
GO-Script Reverse Transcription Kit and used in Real-Time PCR. Briefly, cDNA samples 
were subject to Taqman assay performed on a Roche Lightcycler. Results are reported as 
expression levels were calculated using the Δct method relative to HPRT. 
Video imaging of the calcium response in living cells 
Experiments on parent cell lines 
T-cells were loaded with Fura-PE3-AM (1 μM) at room temperature for 30 min in Hank’s 
Balanced Salt Solution (HBSS). After washing, the cells were incubated for 15 min in the 
absence of Fura-PE3-AM to complete de-esterification of the dye. Cells were placed in a 
temperature controlled chamber (37°C) of an inverted epifluorescence microscope (Olympus 
IX70) equipped with an x40 UApo/340–1.15 W water-immersion objective (Olympus), and 
fluorescence micrograph images were captured at 510 nm and 12-bit resolution by a fast-scan 
camera (CoolSNAP fx Monochrome, Photometrics). To minimize UV light exposure, a 4×4 
binning function was used. Fura-PE3 was alternately excited at 340 and 380 nm, and the ratios 
of the resulting images (emission filter at 520 nm) were produced at constant intervals (10 
seconds). The Fura-PE3 ratio (Fratio 340/380) images were analyzed offline with Universal 
Imaging software, including Metafluor and Metamorph. Fratio reflects the intracellular Ca
2+
 
concentration changes. Each experiment was repeated at least 3 times, and the average of 
more than 20 single-cell traces per experiment was analyzed. 
Experiments on GFP-expressing cell lines 
Fluo2-AM was used, instead of Fura-PE3-AM for experiments with GFP-expressing cells, 
because GFP fluorescence interferes with Ca2+ measurement using Fura-PE3. As 
aforementioned, T cells were loaded with Fluo2-AM (1 μM) for 30 min in Hank’s Balanced 
Salt Solution (HBSS) and then incubated for 15 min in the Fluo2-AM free HBSS to complete 
de-esterification of the dye. Ca2+ changes were evaluated by exciting Fluo2-AM-loaded cells 
at 535 ± 35 nm. The values of the emitted fluorescence (605 ± 50 nm) for each cell (F) were 
normalized to the starting fluorescence (F0) and reported as F/F0 (relative Ca2+ [CYT]). Only GFP-
positive cells were included in the analysis as described above. 
Modelling 
In supporting Materials and Methods. 
Statistical analysis 
Data were tested for normality prior to analysis in Prism 6.04 (Graphpad), data were analyzed 
by a combination of students t-tests, Mann-Whitney U test, 1-way Anova or 2-way Anova’s 
with a Bonferroni correction for multiple group comparisons. A p<0.05 was considered 
significant, specific tests and p values are indicated in the relevant graphs. 
Alanine scanning. 
Alanine scanning was performed on 18 amino acid residues of the CID N-terminus region of 
CD95. Using pcDNA3.1-HA-CD95 (WT), plasmid encoding the different human CD95 
mutants were generated by QuikChange Site-directed mutagenesis (Agilent technologies) 
with the following set of primers: K175A- 
(GTCCAGTGTGGTGGAATTCATGGCGAGAAAGGAAGTACAG and 
CTGTACTTCCTTTCTCGCCATGAATTCCACCACACTGGAC); R176A- 
(GTGGTGGAATTCATGAAGGCAAAGGAAGTACAGAAAACATGCAG and 
CTGCATGTTTTCTGTACTTCCTTTGCCTTCATGAATTCCACCAC); K177A- 
(GGTGGAATTCATGAAGAGAGCGGAAGTACAGAAAACATGCAG and 
CTGCATGTTTTCTGTACTTCCGCTCTCTTCATGAATTCCACC); E178A- 
(GGAATTCATGAAGAGAAAGGCAGTACAGAAAACATGCAGAAAGC and 
GCTTTCTGCATGTTTTCTGTACTGCCTTTCTCTTCATGAATTCC); V179A- 
(GGTGGAATTCATGAAGAGAAAGGAAGCACAGAAAACATGCAG and 
CTGCATGTTTTCTGTGCTTCCTTTCTCTTCATGAATTCCACC); Q180A- 
(GTGTGGTGGAATTCATGAAGAGAAAGGAAGTAGCGAAAACATGC and 
GCATGTTTTCGCTACTTCCTTTCTCTTCATGAATTCCACCACAC); K181A- 
(GGAAGTACAGGCAACATGCAGAAAGCACAGAAAGGAAAACC and 
GGTTTTCCTTTCTGTGCTTTCTGCATGTTGCCTGTACTTCC); T182A- 
(GGTGGAATTCATGAAGAGAAAGGAAGTACAGAAAGCATGCAG and 
CTGCATGCTTTCTGTACTTCCTTTCTCTTCATGAATTCCACC); C183A- 
(GGAAGTACAGAAAACAGCCAGAAAGCACAGAAAGGAAAACC and 
GGTTTTCCTTTCTGTGCTTTCTGGCTGTTTTCTGTACTTCC); R184A- 
(GTACAGAAAACATGCGCAAAGCACAGAAAGGAAAACCAAGG and 
CCTTGGTTTTCCTTTCTGTGCTTTGCGCATGTTTTCTGTAC); K185A- 
(GGAAGTACAGAAAACATGCAGAGCGCACAGAAAGGAAAACC and 
GGTTTTCCTTTCTGTGCGCTCTGCATGTTTTCTGTACTTCC); H186A- 
(GCAGAAAGGCCAGAAAGGAAAACCAAGGTTCTCATGAATCTCC and 
GGAGATTCATGAGAACCTTGGTTTTCCTTTCTGGCCTTTCTGC); R187A- 
(GCAGAAAGCACGCAAAGGAAAACCAAGGTTCTCATGAATCTCC and 
GGAGATTCATGAGAACCTTGGTTTTCCTTTGCGTGCTTTCTGC); K188A- 
(GCAGAAAGCACAGAGCGGAAAACCAAGGTTCTCATGAATCTCC and 
GGAGATTCATGAGAACCTTGGTTTTCCGCTCTGTGCTTTCTGC); E189A- 
(GCACAGAAAGGCAAACCAAGGTTCTCATGAATCTCCAACC and 
GGTTGGAGATTCATGAGAACCTTGGTTTGCCTTTCTGTGC); N190A- 
(GGAAGCCCAAGGTTCTCATGAATCTCCAACCTTAAATCC and 
GGATTTAAGGTTGGAGATTCATGAGAACCTTGGGCTTCC); Q191A- 
(GCAGAAAGCACAGAAAGGAAAACGCAGGTTCTCATGAATCTCC and 
GGAGATTCATGAGAACCTGCGTTTTCCTTTCTGTGCTTTCTGC); G192A- 
(GCACAGAAAGGAAAACCAAGCGTCTCATGAATCTCCAACC and 
GGTTGGAGATTCATGAGACGCTTGGTTTTCCTTTCTGTGC). R184A-K185A 
(GGAAGTACAGAAAACATGCGCAGCGCACAGAAAGGAAAACCAAGG and 
CCTTGGTTTTCCTTTCTGTGCGCTGCGCATGTTTTCTGTACTTCC). The double mutant 
CD95 (R184A-K185A - DM) was used as template to generate the triple mutant CD95 
( R 1 8 4 A - K 1 8 5 A - K 1 8 8 A  -  T M )  w i t h  t h e  f o l l o w i n g  s e t  o f  p r i m e r s :  
(GCGCAGCGCACAGAGCGGAAAACCAAGGTTCTCATG and  
CATGAGAACCTTGGTTTTCCGCTCTGTGCGCTGCGC). 
Proximity Ligation Assay (PLA) 
CEM, CEM-IRC (low CD95-expressing CEM cells) cell lines and Th17 cells isolated from 
human peripheral blood were let adhere to poly-L-lysine-coated slides for 15 min at 37°C. 
Then, cells were stimulated with or without cl-CD95L (100 ng/mL) for indicated times at 
37°C. After 2 washes with PBS, cells were fixed and permeabilized with PFA (4%) for 20 min 
at RT. Cells were blocked with PBS-5% FCS for 20 min at RT, then incubated for 20 min at 
4°C with a mix of primary antibodies containing rabbit anti-human CD95 (C-20) and mouse 
anti-PLCγ1 (05-163) diluted to 1:400 in PBS-5% FCS. The ligation and rolling circle 
amplification reactions (Olink Bioscience) were performed following the manufacturer’s 
recommendations. Finally, nuclei were stained with DAPI and cells were mounted on slides 
with coverslips for confocal microscopy analysis. 
Interaction of CID and PLCγ1 
Homology modelling. 
Side chains of co-crystallized peptide (PDB: 1YWO, (Deng et al., 2005)) were replaced by 
the CID amino acids. For the sequence alignment, we only postulated that a salt bridge 
involving Asp808 or Glu809 should be conserved, setting a basic residue in the COOH 
terminus of the CID peptide. Ten possible sequence alignments met this criterion. The 
corresponding crude homology models were then optimized through energy minimization 
procedures. The modelled complex with the lowest free energy and the highest interaction 
energy was finally submitted to 30 cycles of simulated annealing (30 successive steps of 
heating to 700 K then cooling to 300 K). 
Protein-protein docking. 
The CID was truncated into all possible heptapeptides according to the prerequisite that they 
contained at least one basic residue. Before docking, the peptides were equilibrated by a short 
(50 ps) molecular dynamics at 300 K, using a generalized Born implicit solvent model. ZDock 
and ZRank were used for peptide protein docking. (Chen and Weng, 2002; Pierce and Weng, 
2007). The 30 best predicted complexes were refined with RDock (Li et al., 2003). As above, 
the modelled complex with the lowest free energy and the highest interaction energy was 
finally submitted to 30 cycles of simulated annealing. Both methods predicted that the peptide 
TCRKHRK could have the highest affinity for PLCγ1 SH3 domain. 
Protein-peptide interaction energy. 
The binding free energy was calculated with CHARMm, using CHARMm force-field. A 
nonbond list radius of 20 Å was used, with distance-dependant dielectrics (E=1). The 
interaction energy is the difference between energy of the complex and that of its individual 
components (receptor and ‘ligand’), dissected into van der Waals and electrostatic 
contributions. 
Analysis of CID 3D structure 
The structure of peptide KRKEVQKTCRKHRKENQGSHESPTLNPETVAINLSD was 
investigated by molecular dynamics to test its autonomous folding ability. The simulation 
started from an extended conformation of the peptide, immersed in a rectangular solvent box 
of 25 x 46 x 129 Å, under periodic boundary conditions. The system was neutralized and 
brought to 145 mM ionic strength by addition of Na+ and Cl- ions (5597 water molecules, 15 
Na+ and 18 Cl-). Using CHARMm force field implemented in Discovery Studio 4.1 
(Accelrys, San Diego, CA) and NAMD 2.9, the system was prepared by 6000 steps of steepest 
descent energy minimization, followed by 6000 steps of adopted Newton-Raphson protocol. 
The system was heated up to 300 K over a period of 40 ps with a 1 fs time step, then 
equilibrated for 50 ps. A 12 ns production run was performed at 300 K and carried out under 
NPT conditions, with a 1 fs time step. Particle mash Ewald (PME) was employed to calculate 
the long-range electronic interactions. Trajectories were analyzed with Discovery Studio. No 
secondary structure formation was observed in this simulation. 
To ensure that explicit solvent modeling did not restrict the folding propensity of the peptide, 
and that our simulation time was not too restrictive to see a slow-occurring event, a 40 ns 
simulation was also ran with implicit solvent representation (Generalized Born with a simple 
swithcing), under CHARMM 37.2. These parameters of molecular dynamics can be viewed as 
accelerated conditions. 
Analysis of hydrogen bonds was performed with VMD1.9.1 (Humphrey et al., 1996). The 
following parameters were used to define hydrogen bonds: donnor-acceptor distance < 3 Å , 
and angle cutoff < 20°. 
References: 
Beneteau, M., Daburon, S., Moreau, J.F., Taupin, J.L., and Legembre, P. (2007). Dominant-
negative Fas mutation is reversed by down-expression of c-FLIP. Cancer Res 67, 108-115. 
Beneteau, M., Pizon, M., Chaigne-Delalande, B., Daburon, S., Moreau, P., De Giorgi, F., 
Ichas, F., Rebillard, A., Dimanche-Boitrel, M.T., Taupin, J.L., et al. (2008). Localization of 
Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase 
signaling pathway. Mol Cancer Res 6, 604-613. 
Chen, R., and Weng, Z. (2002). Docking unbound proteins using shape complementarity, 
desolvation, and electrostatics. Proteins 47, 281-294. 
Deng, L., Velikovsky, C.A., Swaminathan, C.P., Cho, S., and Mariuzza, R.A. (2005). 
Structural basis for recognition of the T cell adaptor protein SLP-76 by the SH3 domain of 
phospholipase Cgamma1. Journal of molecular biology 352, 1-10. 
Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD: visual molecular dynamics. Journal 
of molecular graphics 14, 33-38, 27-38. 
Jaffe, E.A., Nachman, R.L., Becker, C.G., and Minick, C.R. (1973). Culture of human 
endothelial cells derived from umbilical veins. Identification by morphologic and 
immunologic criteria. J Clin Invest 52, 2745-2756. 
Kikawada, E., Lenda, D.M., and Kelley, V.R. (2003). IL-12 deficiency in MRL-Fas(lpr) mice 
delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology. J 
Immunol 170, 3915-3925. 
Li, L., Chen, R., and Weng, Z. (2003). RDOCK: refinement of rigid-body protein docking 
predictions. Proteins 53, 693-707. 
Pierce, B., and Weng, Z. (2007). ZRANK: reranking protein docking predictions with an 
optimized energy function. Proteins 67, 1078-1086. 
Stefan, E., Aquin, S., Berger, N., Landry, C.R., Nyfeler, B., Bouvier, M., and Michnick, S.W. 
(2007). Quantification of dynamic protein complexes using Renilla luciferase fragment 
complementation applied to protein kinase A activities in vivo. Proc Natl Acad Sci U S A 104, 
16916-16921. 
Tauzin, S., Chaigne-Delalande, B., Selva, E., Khadra, N., Daburon, S., Contin-Bordes, C., 
Blanco, P., Le Seyec, J., Ducret, T., Counillon, L., et al. (2011). The naturally processed 
CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol 9, e1001090. 
Supporting tables 2 and 3 Click here to download Supplemental Text & Figures Tables 
.docx 
Table 2 
 Relative fold change 
Gene symbol Th17 stimulated vs. unstimulated Treg stimulated vs. unstimulated 
VPS37A -1.2187 1.0262 
DRP2 -1.10687 1.11192 
EFCAB5 -1.12642 1.14751 
COQ4 -1.04827 1.10438 
ZNF320 1.61477 1.18599 
PSMC2 1.15354 -1.05771 
ARHGEF26-AS1 -1.07685 1.11781 
OR10H2 -1.12673 1.11702 
UNC45A -1.14011 1.25001 
EPAS1 1.08741 -1.34553 
ANTXRLP1 -1.14168 1.08615 
TMEM25 -1.24294 1.08011 
ZNF593 -1.41109 1.32329 
SERPINB4 -1.18064 1.56211 
ABHD12B 1.09144 -1.07552 
MAP3K9 -1.14526 1.24006 
ZDHHC22 -1.27771 1.0938 
CHD1L -1.14274 1.13755 
MDFIC 1.08706 -1.03476 
TRIM34 1.45832 -1.546 
LOC101928137 -1.1616 1.15176 
PRSS41 -1.23148 1.25143 
SNORD35A -1.37603 1.14985 
TMEM237 -1.29511 1.3264 
TMCC1-AS1 1.28487 -1.15848 
RPL27 -1.09928 1.0452 
ZCCHC8 -1.10625 1.19871 
FCRL5 -1.28279 1.24124 
SSR2 -1.03722 1.02959 
FMOD 1.05909 -1.20482 
ACTA2 -1.31173 1.2085 
LRRC8E -1.22236 1.12693 
LIPM -1.25676 1.13371 
HKDC1 -1.07502 -1.2326 
WWOX -1.26201 1.1755 
TMEM87A 1.06298 -1.04883 
ESRP1 -1.06348 1.19337 
M1AP -1.08421 1.2416 
PPP1R3E 1.12114 -1.23311 
PPIEL 1.45727 -1.67878 
CSMD2 1.08532 -1.11359 
SLC2A4RG 1.06634 1.16064 
CASC4 -1.0574 1.15611 
INGX -1.45982 -1.16203 
GPR35 1.25408 1.06576 
SLC22A23 1.61737 -1.54163 
KLK8 1.22631 -1.27387 
RPL30 -1.06549 1.0249 
C1orf127 -1.11039 1.13547 
C10orf120 -1.13776 1.24363 
FABP3 -1.19801 1.35184 
CACNA1C 1.11104 -1.06552 
RTF1 1.09766 -1.05759 
SRD5A1 1.32915 2.31024 
BAG4 -1.22314 1.0878 
PKD2L2 -1.13438 1.18495 
LOC100147773 -1.11951 1.2163 
SH2D5 1.0991 -1.14987 
TP53TG5 -1.12766 1.30732 
POU1F1 -1.10557 1.13973 
NEK11 1.13472 -1.12905 
TMEM217 1.25413 -1.24333 
TRMT2A -1.32245 1.41185 
INTS12 1.4251 -1.19657 
SLC2A6 1.1417 -1.23887 
CCDC115 1.24743 -1.24976 
LY6G5B 1.13385 -1.1463 
SPCS3 -1.11826 1.07262 
DMRT1 1.2028 -1.14724 
HAT1 1.08729 -1.07063 
ILVBL -1.12258 1.18317 
SRCAP -1.0353 -1.09103 
LEFTY2 1.10244 -1.16611 
SHOX 1.12646 -1.18587 
NT5M -1.15682 1.21646 
OR52B6 -1.37374 -1.13402 
NEFH -1.43191 1.29372 
TIMM50 -1.22016 1.11546 
POFUT1 -1.47131 1.25275 
AKR1E2 -1.19215 1.2851 
TOR1AIP2 -1.14966 1.15281 
PRKX -1.15509 1.08747  
TMEM185A -1.51088 1.67266 
SLC52A2 -1.34327 -1.1658 
SNORD26 1.87475 1.21237 
CST6 1.2842 -1.29235 
LRRC25 1.15555 -1.12413 
H6PD 1.32607 -1.2362 
SYNPR-AS1 1.09846 -1.11393 
CDC25C -1.13046 1.16973 
DEGS1 -1.1544 1.10171 
METTL22 -1.20282 1.35427 
USP33 1.05299 -1.07997 
LSM2 -1.20621 1.25728 
NAGPA-AS1 1.36308 -1.30974 
SPATA16 -1.10578 1.17315 
SIK2 -1.11015 1.09226 
TESK1 1.14216 -1.11076 
GDF7 1.2847 -1.24163 
PDGFA -1.1632 1.22555 
APOL6 -1.17229 1.24684 
CLPSL1 -1.52283 1.59385 
CA5A 1.19717 -1.22226 
SRP72 -1.14804 1.12069 
PDZK1P1 1.53006 -1.31707 
ING4 1.17924 1.07232 
LOC151475 1.11323 -1.14249 
ATL3 1.10334 -1.1102 
INSL5 -1.11944 1.11316 
SCARNA18 -1.25352 1.28597 
SYT3 -1.29511 1.40158 
SPRYD4 1.20739 -1.1953 
C1orf131 -1.21725 1.23301 
TTC25 1.17828 -1.15539 
ALKBH4 -1.07622 1.10393 
ATRN -1.30582 1.27042 
RPS6KA6 -1.05998 1.07829 
BID -1.19751 1.20292 
DSN1 -1.28303 1.35944 
ZNF784 1.22333 -1.22918 
SNORD68 -1.27358 1.25698 
HS2ST1 1.13012 -1.16941 
OR4K2 1.30299 1.75232 
CHCHD7 -1.14312 1.16837 
CLIP1-AS1 -1.32616 1.41305 
MCM8-AS1 -1.16863 1.18131 
KLHL24 1.11751 -1.10213  
PLAC4 -1.13376 1.14628 
LRP3 1.32716 -1.32789 
C2orf91 -1.07535 1.06961 
SIX1 1.44105 1.14412 
DPH7 1.11451 1.24272 
DDX11L2 -1.11509 -1.34592 
MMAA 1.46051 1.15721 
GALNT2 1.12559 1.31587 
OTUD5 -1.09547 -1.06426 
FBXO36 1.32015 1.65663 
LURAP1L -1.13323 -1.29686 
C5orf66-AS2 -1.28941 -1.11341 
BCL2 -1.08503 -1.0531 
ARHGAP5-AS1 1.31924 1.13897 
C19orf18 -1.20012 -1.11286 
ADGRA1 -1.15439 -1.07138 
RNF148 -1.08177 -1.1859 
TMEM210 -1.10993 -1.21879 
RBCK1 -1.20302 -1.09486 
ARHGEF1 1.18057 1.08836 
SHCBP1L 1.24008 1.11491 
IGLV1-36 -1.4841 -1.29077 
USP32P2 -1.29373 -1.47477 
HSPB8 -1.99048 -1.49988 
HAND1 -1.12342 -1.18305 
PCNT 1.14886 1.09722 
ZCRB1 -1.07858 -1.12106 
IVL -1.26819 -1.14587 
COPS8 1.10942 1.19805 
MGC27345 1.15671 1.08599 
LOC101929535 -1.5817 -1.34716 
LOC102724601 1.46406 1.29181 
GAP43 1.17197 1.10154 
LOC105379199 1.24456 1.40182 
WDR53 1.2846 1.20216 
LCMT1 1.28844 1.19265 
ZDBF2 1.24196 1.14491 
PTGES -1.25126 -1.15699 
RAPGEFL1 -1.38324 -1.24881 
CST9 -1.1839 -1.12207 
SHISA8 1.13489 1.21189 
ATP7A 1.10166 1.15869 
CPNE3 1.1477 1.09696 
IFT172 1.16901 1.23831 
BLM 1.18573 1.28079  
C11orf73 -1.2721 -1.17797 
UBE2V1 -1.14878 -1.21568 
KRTAP4-9 1.19343 1.13179 
OR5D14 1.12948 1.18809 
KIAA1841 1.4017 1.29562 
WDR73 1.16109 1.22799 
IRX2 1.19533 1.26302 
HMCES 1.12237 1.1604 
ELMO1-AS1 1.16908 1.22775 
FBXW5 1.19286 1.23759 
SLC30A3 -1.19013 -1.14602 
OR6C1 -1.29203 -1.3965 
CCT6P1 -1.12871 -1.17264 
TPH1 1.2292 1.31369 
CORO6 1.06195 1.07515 
OR1E2 1.56246 1.77816 
PIPOX -1.34905 -1.2921 
OR52B2 1.37861 1.45931 
PCGF2 -1.22419 -1.19613 
FRMD4B -1.16392 -1.14172 
ARL6IP5 -1.10182 -1.12815 
KIAA0556 -1.15403 -1.12386 
ADRB1 1.21126 1.22485 
HEATR5B 1.08451 1.069 
ARRDC3-AS1 1.23716 1.20817 
XPR1 1.18221 1.20406 
KRT15 -1.1246 -1.11097 
TNFRSF25 1.10365 1.11299 
OR7E91P 1.33727 1.30031 
FAM110B 1.42099 1.47063 
TINCR 1.26521 1.28952 
FOXJ1 -1.16162 -1.15162 
DCTN3 1.15639 1.16989 
CYP27B1 -1.31417 -1.29011 
ZDHHC12 -1.16082 -1.17618 
DND1 1.2409 1.22655 
MCM2 -1.15025 -1.16232 
TRIM38 1.24168 1.22226 
NDUFS6 1.11494 1.12303 
PRPF18 1.05949 1.05506 
CCDC34 1.23192 1.22054 
KNDC1 -1.20552 -1.2185 
PLEKHG5 -1.22472 -1.21315 
MCOLN3 1.1003 1.09479 
RNF175 1.70441 1.73551 
ADAM5 1.10845 1.10604 
GAS2L3 1.39535 1.40747 
TSPAN6 -1.13706 -1.13916 
SNORD114-28 1.07227 1.07043 
CRYM-AS1 -1.15133 -1.15436 
RNF113B -1.17185 -1.16885 
AXIN1 1.15534 1.1523 
DEFB124 1.21256 1.21163 
RGAG1 -1.25306 -1.25427  
Supporting Table 2. Calculated binding energies of CID heptapeptides to PLCγ1-SH3 
domain. 
Relative fold change in the quantity of transcripts significantly (p ≤ 0.05) and differentially 
expressed in Th17 and Treg cells stimulated vs unstimulated with cl-CD95L (100 ng/mL). 
Data for each experimental group (n = 2 per condition) are shown. 
Table 3 
interaction 
energy 
(kcal/mol) 
van der  
Waals  
energy  
(kcal/mol) 
Ligand  
Contact  
Surface 
Area 
(Å) 
Receptor  
Contact  
Surface 
Area 
(Å) 
RMSD 
vs 
1YWO 
all 
heavy 
atoms 
(Å) 
RMSD vs 
1YWO  
backbone 
atoms 
(Å) 
Predicted SH3-PLCγ1 / CID-CD95 complex (TCRKHRK peptide) 
protein protein  
docking 
-122 -26.5 203 200 na na 
homology modelling -143 -24.4 225 222 na na 
SH3-PLCγ1 / SLP-76 complex (PPVPPQR peptide) 
 
PDB : 1YWO -118 -35 238 229 0 0 
redocking (pose 6) -90 -40 238 232 6.6 5.1 
redocking (pose 29) -118 -37 243 233 2.2 2.2 
       
protein protein  
docking (pose 10) 
-98 -36 220 218 5.5 3.6 
protein protein  
docking (pose 20) 
-138 -30 236 213 3.9 2.5 
Supporting Table 3. Calculated binding energies of CID heptapeptides to PLCγ1-SH3 
domain. 
The binding energy computed for the best complex obtained by the two molecular modelling 
approaches is compared to calculated binding energy of the PLCγ1 SH3 - SLP-76 complex. 
This control is either the co-crystallized molecules (PDB:1YWO), redocking of SLP-76 
(protein-protein docking, using co-crystallized conformations), or protein-protein docking 
using the same protocol as for CID docking (short molecular dynamics simulation of the free 
peptide, then protein-protein docking). 
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